1
|
Ladetto M, Tavarozzi R, Zanni M, Evangelista A, Ferrero S, Tucci A, Botto B, Bolis S, Volpetti S, Zilioli VR, Puccini B, Arcari A, Pavone V, Gaidano G, Corradini P, Tani M, Cavallo F, Milone G, Ghiggi C, Pinto A, Pastore D, Ferreri AJM, Latte G, Patti C, Re F, Benedetti F, Luminari S, Pennese E, Bossi E, Boccomini C, Anastasia A, Bottelli C, Ciccone G, Vitolo U. Radioimmunotherapy versus autologous hematopoietic stem cell transplantation in relapsed/refractory follicular lymphoma: a Fondazione Italiana Linfomi multicenter, randomized, phase III trial. Ann Oncol 2024; 35:118-129. [PMID: 37922989 DOI: 10.1016/j.annonc.2023.10.095] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2023] [Revised: 09/11/2023] [Accepted: 10/03/2023] [Indexed: 11/07/2023] Open
Abstract
BACKGROUND Optimal consolidation for young patilents with relapsed/refractory (R/R) follicular lymphoma (FL) remains uncertain in the rituximab era, with an unclear benefit of autologous stem cell transplantation (ASCT). The multicenter, randomized, phase III FLAZ12 (NCT01827605) trial compared anti-CD20 radioimmunotherapy (RIT) with ASCT as consolidation after chemoimmunotherapy, both followed by rituximab maintenance. PATIENTS AND METHODS Patients (age 18-65 years) with R/R FL and without significant comorbidities were enrolled and treated with three courses of conventional, investigator-chosen chemoimmunotherapies. Those experiencing at least a partial response were randomized 1 : 1 to ASCT or RIT before CD34+ collection, and all received postconsolidation rituximab maintenance. Progression-free survival (PFS) was the primary endpoint. The target sample size was 210 (105/group). RESULTS Between August 2012 and September 2019, of 164 screened patients, 159 were enrolled [median age 57 (interquartile range 49-62) years, 55% male, 57% stage IV, 20% bulky disease]. The study was closed prematurely because of low accrual. Data were analyzed on 8 June 2023, on an intention-to-treat basis, with a 77-month median follow-up from enrollment. Of the 141 patients (89%), 70 were randomized to ASCT and 71 to RIT. The estimated 3-year PFS in both groups was 62% (hazard ratio 1.11, 95% confidence interval 0.69-1.80, P = 0.6662). The 3-year overall survival also was similar between the two groups. Rates of grade ≥3 hematological toxicity were 94% with ASCT versus 46% with RIT (P < 0.001), and grade ≥3 neutropenia occurred in 94% versus 41%, respectively (P < 0.001). Second cancers occurred in nine patients after ASCT and three after radioimmunotherapy (P = 0.189). CONCLUSIONS Even if prematurely discontinued, our study did not demonstrate the superiority of ASCT versus RIT. ASCT was more toxic and demanding for patients and health services. Both strategies yielded similar, favorable long-term outcomes, suggesting that consolidation programs milder than ASCT require further investigation in R/R FL.
Collapse
Affiliation(s)
- M Ladetto
- Department of Translational Medicine, University of Eastern Piedmont, Novara; SCDU di Ematologia, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, Alessandria.
| | - R Tavarozzi
- Department of Translational Medicine, University of Eastern Piedmont, Novara; SCDU di Ematologia, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, Alessandria
| | - M Zanni
- SCDU di Ematologia, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, Alessandria
| | - A Evangelista
- SSD of Clinical Epidemiology, Universitaria Città della Salute e della Scienza di Torino and Centre for Cancer Prevention Piemonte, Torino
| | - S Ferrero
- Department of Molecular Biotechnologies and Health Sciences, Universitaria Città della Salute e della Scienza di Torino and Centre for Cancer Prevention Piemonte, Torino
| | - A Tucci
- Department of Hematology, Spedali Civili, Brescia
| | - B Botto
- Struttura Complessa Ematologia, AOU Città della salute e della scienza di Torino, Turin
| | - S Bolis
- SC Ematologia ASST-Monza, Monza
| | - S Volpetti
- Division of Hematology, Clinica Ematologica, Centro Trapianti e Terapie Cellulari Carlo Melzi, DISM, Azienda Ospedaliero Universitaria S. M. Misericordia, Udine
| | - V R Zilioli
- Division of Haematology, ASST Grande Ospedale Metropolitano Niguarda, Milano
| | - B Puccini
- Department of Haematology, University of Florence, Firenze
| | - A Arcari
- Hematology Unit, Ospedale Guglielmo da Saliceto, Piacenza
| | - V Pavone
- A. O. C. Panico-U.O.C Ematologia e Trapianto, Tricase, Lecce
| | - G Gaidano
- SCDU di Ematologia, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, Alessandria; Division of Hematology, Azienda Ospedaliero-Universitaria Maggiore della Carità, Novara
| | - P Corradini
- Division of Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, University of Milan, Milano
| | - M Tani
- Hematology Unit, Department of Oncology and Hematology, "Santa Maria delle Croci" Hospital, Ravenna
| | - F Cavallo
- Department of Molecular Biotechnologies and Health Sciences, Universitaria Città della Salute e della Scienza di Torino and Centre for Cancer Prevention Piemonte, Torino
| | - G Milone
- Division of Hematology and Program for Hematopoietic Transplantation, Azienda Ospedaliera Policlinico Vittorio Emanuele, Catania
| | - C Ghiggi
- Hematology Division, IRCCS Azienda Ospedaliera Universitaria San Martino, IST Istituto Nazionale per la Ricerca sul Cancro, Genova
| | - A Pinto
- Department of Hematology, Istituto Nazionale Tumori Istituto di Ricovero e Cura a Carattere Scientifico "Fondazione G Pascale", Naples
| | | | - A J M Ferreri
- Onco-Hematology Department, Fondazione Centro San Raffaele, Milano
| | - G Latte
- Unità di Ematologia e Trapianto di Midollo Osseo, San Francesco Hospital, Nuoro
| | - C Patti
- Divisione di Oncoematologia, Azienda Villa Sofia - Cervello, Palermo
| | - F Re
- Department of Hematology, A.O.U. di Parma, Parma
| | - F Benedetti
- Department of Medicine, Section of Hematology and Bone Marrow Transplant Unit, University of Verona, Verona
| | - S Luminari
- Department of Hematology, IRCCS Reggio Emilia, Reggio Emilia
| | - E Pennese
- Lymphoma Unit, Department of Hematology, Ospedale Spirito Santo, Pescara
| | - E Bossi
- SC Ematologia ASST-Monza, Monza
| | - C Boccomini
- Struttura Complessa Ematologia, AOU Città della salute e della scienza di Torino, Turin
| | - A Anastasia
- Department of Hematology, Spedali Civili, Brescia
| | - C Bottelli
- Department of Hematology, Spedali Civili, Brescia
| | - G Ciccone
- SSD of Clinical Epidemiology, Universitaria Città della Salute e della Scienza di Torino and Centre for Cancer Prevention Piemonte, Torino
| | - U Vitolo
- Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy
| |
Collapse
|
2
|
Limoncin E, Ciocca G, Castellini G, Sansone A, Cavalieri F, Cavallo F, Cocchiaro T, Ricca V, di Lorenzo G, Rossi A, Fisher AD, Rochira V, Corona G, Jannini EA. Hypersexuality as a tip of the iceberg of a primary psychopathology: a joined position statement of the Italian Society of Andrology and Sexual Medicine (SIAMS) and of the Italian Society of Psychopathology (SOPSI). J Endocrinol Invest 2022; 45:1787-1799. [PMID: 35527295 DOI: 10.1007/s40618-022-01798-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/28/2022] [Accepted: 03/28/2022] [Indexed: 10/18/2022]
Abstract
In the last years, hypersexual behavior has been broadly scientifically studied. The interest in this topic, belonging to psycho-sexology and sexual medicine, has been due to its still unclear aetiology, nature, and its manifestation in relationship with several organic and psychopathological conditions. So, the specialist (the psychologist, psychiatrist, endocrinologist, neurologist) may encounter some difficulties in diagnosing and managing this symptom. The first main objective of this position statement, which has been developed in collaboration between the Italian Society of Andrology and Sexual Medicine (SIAMS) and the Italian Society of Psychopathology (SOPSI) is to give to the reader evidence about the necessity to consider hypersexuality as a symptom related to another underlying condition. Following this consideration, the second main objective is to give specific statements, for the biopsychosocial assessment and the diagnosis of hypersexual behavior, developed on the basis of the most recent literature evidence. To develop a psycho-pharmacological treatment tailored on patients' needs, our suggestion is to assess the presence of specific comorbid psychopathological and organic conditions, and the impact of pharmacological treatments on the presence of an excess of sexual behavior. Finally, a suggestion of a standardized psychometric evaluation of hypersexuality will be given.
Collapse
Affiliation(s)
- E Limoncin
- Endocrinology and Medical Sexology (ENDOSEX), Department of Systems Medicine, University Tor Vergata, E Tower South. Floor 4, Room E413, Via Montpellier 1, 00133, Rome, Italy
- Department of Dynamic, Clinical Psychology and Health, University Sapienza, Rome, Italy
| | - G Ciocca
- Department of Dynamic, Clinical Psychology and Health, University Sapienza, Rome, Italy
| | - G Castellini
- Psychiatric Unit, Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy
| | - A Sansone
- Endocrinology and Medical Sexology (ENDOSEX), Department of Systems Medicine, University Tor Vergata, E Tower South. Floor 4, Room E413, Via Montpellier 1, 00133, Rome, Italy
| | - F Cavalieri
- Department of Medicine, Unit of Andrology and Reproduction Medicine, University of Padova, Padua, Italy
| | - F Cavallo
- Spinal Unit, San Raffaele Institute of Sulmona, Sulmona, Italy
| | - T Cocchiaro
- Department of Gender, Parenting, Child and Adolescent Medicine, Unit of Reproductive Pathophysiology and Andrology, "Sandro Pertini" Hospital, Rome, Italy
| | - V Ricca
- Psychiatric Unit, Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy
| | - G di Lorenzo
- Laboratory of Psychophysiology and Cognitive Neuroscience, Chair of Psychiatry, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy
- Psychiatry and Clinical Psychology Unit, Section of Psychiatry, Fondazione Policlinico Tor Vergata, Rome, Italy
| | - A Rossi
- Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy
| | - A D Fisher
- Sexual Medicine and Andrology Unit, Department of Experimental, Clinical and Biomedical Sciences, University of Florence, Florence, Italy
| | - V Rochira
- Unit of Endocrinology, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy
- Unit of Endocrinology, Department of Medical Specialties, Azienda Ospedaliero-Universitaria of Modena, Modena, Italy
| | - G Corona
- Endocrinology Unit, Medical Department, Maggiore-Bellaria Hospital, Bologna, Italy
| | - E A Jannini
- Endocrinology and Medical Sexology (ENDOSEX), Department of Systems Medicine, University Tor Vergata, E Tower South. Floor 4, Room E413, Via Montpellier 1, 00133, Rome, Italy.
| |
Collapse
|
3
|
Guaitolini M, Rovini E, Galperti G, Fiorini L, Cavallo F. Magnetometer-free Kalman filter for motor-based assessment of prodromal Parkinson's disease. Annu Int Conf IEEE Eng Med Biol Soc 2022; 2022:2395-2398. [PMID: 36086374 DOI: 10.1109/embc48229.2022.9871409] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/15/2023]
Abstract
Observing the kinematics of specific motor tasks, such as finger tapping (FT), provides an objective and consistent quantification of the severity of neurodegenerative diseases. However, the current clinical practice mostly relies on visual observations performed by the clinician. Thus, the assessment is subjective. In this paper, we propose a magnetometer-free Kalman filter (KF) to assess FT features using wearable, inertial sensors. The KF was used to assess features during two different FT tasks, namely forefinger tapping (FTAP) and thumb-forefinger tapping (THFF). The proposed KF was validated against a camera-based reference and compared with a strap-down integration-based method. Comparison between KF method and camera reference showed low discrepancies in terms of root mean square error (RMSE) for considered features: namely number of repetitions (RMSE < 0.7), tapping frequency (RMSE < 0.1 Hz), and amplitude (RMSE < 2.6 deg). An high correlation coefficient between amplitudes was also obtained. The proposed KF performed better than the strap-down integration method on both FT tasks, showing lower RMSE on every feature as well as a higher correlation coefficient. Clinical Relevance- The wearable setup, as well as the proposed magnetometer-free KF, may provide a low-cost, easyto- use, non-invasive motion tracking system for protocols aimed to assess motor performances in neurodegenerative disorders.
Collapse
|
4
|
Avallone G, Cavallo F, Astrua C, Caldarola G, Conforti C, De Simone C, di Meo N, di Stefani A, Genovese G, Maronese CA, Marzano AV, Parente R, Quaglino P, Roccuzzo G, Tassone F, Zalaudek I, Senetta R, Ribero S. Cutaneous adverse reaction following SARS-CoV-2 vaccine booster dose: a real-life multicentre experience. J Eur Acad Dermatol Venereol 2022; 36:e876-e879. [PMID: 35771093 PMCID: PMC9349823 DOI: 10.1111/jdv.18386] [Citation(s) in RCA: 15] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- G Avallone
- Dermatology Clinic, Department of Medical Sciences, University of Turin, Turin, Italy
| | - F Cavallo
- Dermatology Clinic, Department of Medical Sciences, University of Turin, Turin, Italy
| | - C Astrua
- Dermatology Clinic, Department of Medical Sciences, University of Turin, Turin, Italy
| | - G Caldarola
- UOC Dermatologia , Dipartimento di scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario "A.Gemelli" , IRCCS, Roma
| | - C Conforti
- Dermatology Clinic, Maggiore Hospital, Trieste, Italy
| | - C De Simone
- UOC Dermatologia , Dipartimento di scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario "A.Gemelli" , IRCCS, Roma.,Sezione di Dermatologia, Dipartimento di Medicina e Chirurgia Traslazionale, Università Cattolica del S.Cuore, Roma
| | - N di Meo
- Dermatology Clinic, Maggiore Hospital, Trieste, Italy
| | - A di Stefani
- UOC Dermatologia , Dipartimento di scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario "A.Gemelli" , IRCCS, Roma
| | - G Genovese
- Dermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.,Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy
| | - C A Maronese
- Dermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.,Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy
| | - A V Marzano
- Dermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.,Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy
| | - R Parente
- Department of Pathology, Humanitas-Gradenigo Hospital, Corso Regina Margherita 8, 10153, Turin, Italy
| | - P Quaglino
- Dermatology Clinic, Department of Medical Sciences, University of Turin, Turin, Italy
| | - G Roccuzzo
- Dermatology Clinic, Department of Medical Sciences, University of Turin, Turin, Italy
| | - F Tassone
- UOC Dermatologia , Dipartimento di scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario "A.Gemelli" , IRCCS, Roma
| | - I Zalaudek
- Dermatology Clinic, Maggiore Hospital, Trieste, Italy
| | - R Senetta
- Department of Oncology, Pathology Unit, University of Turin, Turin, Italy
| | - S Ribero
- Dermatology Clinic, Department of Medical Sciences, University of Turin, Turin, Italy
| |
Collapse
|
5
|
Cavallo F, Caponigro S, Di Minico D, Danaro G, Maida L, Capone L, Nicolini L, Allegretta S, Aquilanti F, Gentile P. PO-1852 SGRT for pre-positioning in SBRT lung treatments: accuracy and efficiency evaluation. Radiother Oncol 2022. [DOI: 10.1016/s0167-8140(22)03815-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
6
|
Levis M, Botto B, Andreis A, Gastino A, Blasi L, Bartoncini S, Giorgi M, Fava A, Cavallo F, Ferrero S, Boccomini C, Orsucci L, Ricardi U. OC-0293 Early detection of chemo and RT-related heart toxicity in lymphoma patients: The CARDIOCARE Project. Radiother Oncol 2022. [DOI: 10.1016/s0167-8140(22)02551-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
7
|
Dantas C, Machado N, Ortet S, Leandro F, Burnard M, Grünloh C, Grguric A, Hörmann V, Fiorini L, Cavallo F, Rovini E, Scano R, Pocs M. The Iterative Model of Ethical Analysis for Large-Scale Implementation Of ICT Solutions. Transl Med UniSa 2021; 23:1-9. [PMID: 34447702 PMCID: PMC8370527 DOI: 10.37825/2239-9747.1023] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/01/2022]
Abstract
This manuscript presents a model and the methodology to understand and define the ethical management of the large-scale implementation of ICT solutions for Active and Healthy Ageing. Based on project expertise, including experience from the Pharaon project Horizon 2020, this model includes an understanding of the main ethical challenges and the development of the necessary guidelines, measures, and tools for different stakeholder profiles. This model extends beyond conventional ethical guidelines, providing a methodology to actively discuss ethical and societal challenges within a project based on interactive and iterative dialogue between the entire value-chain of stakeholders. One of the cornerstones in the analysis of challenges is focused attention on policy and societal issues that emerge during a project. Accordingly, the model includes targeted reflections and tools delivered in the context of the recent Covid-19 pandemic. The tools developed in this process are organised in a guide that can be actively used throughout large-scale implementation projects related to ICT solutions.
Collapse
Affiliation(s)
- C Dantas
- Innovation Department, Cáritas Diocesana de Coimbra, Portugal
| | - N Machado
- Innovation Department, Cáritas Diocesana de Coimbra, Portugal
| | - S Ortet
- Innovation Department, Cáritas Diocesana de Coimbra, Portugal
| | - F Leandro
- Innovation Department, Cáritas Diocesana de Coimbra, Portugal
| | - M Burnard
- InnoRenew CoE, Slovenia University of Primorska, Andrej Marušič Institute, Slovenia
| | - C Grünloh
- eHealth Group, Roessingh Research and Development, Enschede, The Netherlands Biomedical Signals and Systems Group, University of Twente, Enschede, The Netherlands
| | | | | | - L Fiorini
- The BioRobotics Institute, Scuola Superiore Sant'Anna, Italy. Department of Excellence in Robotics & AI, Scuola Superiore Sant'Anna, Italy
| | - F Cavallo
- The BioRobotics Institute, Scuola Superiore Sant'Anna, Italy. Department of Excellence in Robotics & AI, Scuola Superiore Sant'Anna, Italy.,Department of Industrial Engineering, University of Florence, Italy
| | - E Rovini
- The BioRobotics Institute, Scuola Superiore Sant'Anna, Italy. Department of Excellence in Robotics & AI, Scuola Superiore Sant'Anna, Italy
| | - R Scano
- UNINFO - Associazione di Normazione Informatica, Italy
| | - M Pocs
- Stelar Security Technology Law Research, Germany
| |
Collapse
|
8
|
Cavallo F, Capone L, Gennuso N, Abate G, Grimaldi G, Allegretta S, Russo I, Gentile P. PO-1947 catching opportunity from voxel evaluation of follow-up PET/CT imaging in SBRT of lung lesions. Radiother Oncol 2021. [DOI: 10.1016/s0167-8140(21)08398-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
9
|
Tucci A, Musuraca G, Cavallo F, Zilioli VR, Zanni M, Pelliccia S, Mannina D, Michieli M, Vallisa D, Tani M, Merli F, Re F, Marcheselli L, Campostrini G, Pagani C, Grimaldi D, Liardo EV, Re A, Cox MC, Rossi G. AUTOLOGOUS TRANSPLANT IN ELDERLY PATIENTS WITH R/R AGGRESSIVE LYMPHOMA SELECTED BY SIMPLIFIED CGA: THE RECANZ PROSPECTIVE PHASE 2 STUDY BY THE FONDAZIONE ITALIANA LINFOMI. Hematol Oncol 2021. [DOI: 10.1002/hon.99_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- A Tucci
- ASST Spedali Civili Brescia Hematology Division Brescia Italy
| | - G Musuraca
- IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori" Hematology Unit Meldola (FC) Italy
| | - F Cavallo
- University of To‐rino/AOU “Città della Salute e della Scienza di Torino” Division of Hematology, Department of Molecular Biotechnologies and Health Sciences Torino Italy
| | - V. R Zilioli
- ASST Grande Ospedale Metropolitano Niguarda Division of Hematology Milano Italy
| | - M Zanni
- A.O. SS. Antonio e Biagio e Cesare Arrigo Division of Hematology Alessandria Italy
| | - S Pelliccia
- Hospital Sant’Andrea – Sapienza, Rome Hematology University Roma Italy
| | - D Mannina
- Azienda Ospedaliera Papardo Unit of Hematology Messina Italy
| | - M Michieli
- Aviano (PN) Haematology Transplant and Cell Therapy Unit Aviano (PN) Italy
| | - D Vallisa
- Ospedale Guglielmo da Saliceto Division of Hematology Piacenza Italy
| | - M Tani
- Ospedale delle Croci Department of Hematology Ravenna Italy
| | - F Merli
- Azienda Unità Sanitaria Locale – IRCCS Hematology Unit Reggio Emilia Italy
| | - F Re
- AOU di Parma Hematology Unit Parma Italy
| | - L Marcheselli
- Fondazione Italiana Linfomi Onlus Fondazione Italiana Linfomi Onlus Modena Italy
| | - G Campostrini
- ASST Spedali Civili Brescia Hematology Division Brescia Italy
| | - C Pagani
- ASST Spedali Civili Brescia Hematology Division Brescia Italy
| | - D Grimaldi
- University of To‐rino/AOU “Città della Salute e della Scienza di Torino” Division of Hematology, Department of Molecular Biotechnologies and Health Sciences Torino Italy
| | - E. V Liardo
- IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori" Hematology Unit Meldola (FC) Italy
| | - A Re
- ASST Spedali Civili Brescia Hematology Division Brescia Italy
| | - M. C Cox
- University Hospital Sant’Andrea – Sapienza Hematology Roma Italy
| | - G Rossi
- ASST Spedali Civili Brescia Hematology Division Brescia Italy
| |
Collapse
|
10
|
Trotman J, Tedeschi A, Linton K, McKay P, Hu B, Chan H, Jin J, Sobieraj‐Teague M, Zinzani PL, Coleman M, Browett P, Ke X, Sun M, Marcus R, Portell C, Thieblemont C, Zhou K, Liberati AM, Bachy E, Cavallo F, Costello R, Iyengar S, Marasca R, Mociková H, Kim JS, Talaulikar D, Co M, Zhou W, Huang J, Opat S. SAFETY AND EFFICACY OF ZANUBRUTINIB IN PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA (MAGNOLIA PHASE 2 STUDY). Hematol Oncol 2021. [DOI: 10.1002/hon.19_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- J. Trotman
- Concord Repatriation General Hospital University of Sydney Oncology Concord Australia
| | - A. Tedeschi
- ASST Grande Ospedale Metropolitano Niguarda Hematology Milan Italy
| | - K. Linton
- The Christie Hematology Manchester UK
| | - P. McKay
- Beatson West of Scotland Cancer Centre Oncology Glasgow UK
| | - B. Hu
- Levine Cancer Institute/Atrium Health Oncology Charlotte USA
| | - H. Chan
- North Shore Hospital Haematology Auckland New Zealand
| | - J. Jin
- The First Affiliated Hospital Zhejiang University Hematology Hangzhou China
| | | | - P. L. Zinzani
- Institute of Hematology “Seràgnoli” University of Bologna Hematology Bologna Italy
| | - M. Coleman
- Clinical Research Alliance Hematology Lake Success USA
| | - P. Browett
- Auckland City Hospital Haematology Grafton New Zealand
| | - X. Ke
- Peking University Third Hospital Hematology Beijing China
| | - M. Sun
- Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences Peking Union Medical College Hematology Tianjin China
| | - R. Marcus
- Sarah Cannon Research Institute UK Oncology London UK
| | - C. Portell
- University of Virginia Health System Hematology/Oncology Charlottesville USA
| | - C. Thieblemont
- APHP, Hôpital Saint‐Louis, Hemato‐oncology Paris University Diderot Hematology/Oncology Paris France
| | - K. Zhou
- Henan Cancer Hospital Oncology Zhengzhou China
| | - A. M. Liberati
- Azienda Ospedaliera Santa Maria Di Terni Oncology Terni Italy
| | - E. Bachy
- Centre Hospitalier Lyon Sud Pierre Bénite Hematology Rhone Italy
| | - F. Cavallo
- Azienda Ospedaliera Città della Salute e della Scienza di Torino Hematology Torino Italy
| | - Rég. Costello
- Hôpital de la Conception – APHM Hematology Marseille France
| | - S. Iyengar
- Royal Marsden Hospital Haematology London UK
| | - R. Marasca
- AOU Policlinico di Modena Hematology Modena Italy
| | - H. Mociková
- Fakultní nemocnice Královské Vinohrady Hematology Praha 10 Czech Republic
| | - J. S. Kim
- Severance Hospital Hematology Seoul Korea
| | - D. Talaulikar
- The Canberra Hospital Haematology Canberra Australia
| | - M. Co
- BeiGene (Beijing) Co., Ltd. Beijing, China and BeiGene USA, Inc Hematology San Mateo USA
| | - W. Zhou
- BeiGene (Beijing) Co., Ltd. Beijing, China and BeiGene USA, Inc Hematology San Mateo USA
| | - J. Huang
- BeiGene (Beijing) Co., Ltd. Beijing, China and BeiGene USA, Inc Hematology San Mateo USA
| | - S. Opat
- Monash Health Monash University Haematology Clayton Australia
| |
Collapse
|
11
|
Chiappella A, Carniti C, Re A, Castellino C, Evangelista A, Ciancia R, Orsucci L, Pinto A, Usai SV, Arcari A, Ilariucci F, Rossi FG, Benedetti F, Flenghi L, Ghiggi C, Molinari AL, Stefoni V, Volpetti S, Zilioli VR, Ballerini F, Bruna R, Cavallo F, Musuraca G, Patti C, Re F, Tani M, Varettoni M, Zanni M, Dodero A, Pileri SA, Ciccone G, Corradini P. ROMIDEPSIN‐CHOEP PLUS UP‐FRONT STEM‐CELL TRANSPLANTATION IN PERIPHERAL T‐CELL LYMPHOMA (PTCL): FIRST ANALYSIS OF THE PHASE II FIL‐PTCL13 STUDY. Hematol Oncol 2021. [DOI: 10.1002/hon.130_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- A. Chiappella
- Fondazione IRCCS Istituto Nazionale dei Tumori di Milano Hematology and Stem Cell Transplantation Milano Italy
| | - C. Carniti
- Fondazione IRCCS, Istituto Nazionale dei Tumori di Milano Laboratory of Hematology Division of Hematology and Stem Cell Transplantation Milano Italy
| | - A. Re
- ASST Spedali Civili di Brescia Hematology Division Brescia Italy
| | - C. Castellino
- Azienda Ospedaliera S. Croce e Carle Division of Hematology Cuneo Italy
| | - A. Evangelista
- Azienda Ospedaliera e Universitaria Città della Salute e della Scienza and CPO Piemonte Unit of Clinical Epidemiology Torino Italy
| | - R. Ciancia
- Centro di Riferimento Oncologico (CRO) IRCCS Onco‐hematology and Stem Cell Transplantation and Cellular Therapies Aviano Italy
| | - L. Orsucci
- Azienda Ospedaliera e Universitaria Città della Salute e della Scienza Division of Hematology Torino Italy
| | - A. Pinto
- Istituto Nazionale Tumori, Fondazione G. Pascale, IRCCS Hematology‐Oncology & Stem Cell Transplantation Unit Napoli Italy
| | - S. V. Usai
- Ospedale Oncologico Armando Businco Hematology Cagliari Italy
| | - A. Arcari
- Ospedale Guglielmo da Saliceto Hematology Unit Piacenza Italy
| | - F. Ilariucci
- Azienda USL‐IRCCS, Hematology Reggio Emilia Italy
| | - F. G. Rossi
- Fondazione IRCCS Cà Granda OM Policlinico Division of Hematology Milano Italy
| | - F. Benedetti
- Azienda Ospedaliera Universitaria di Verona Hematology and Stem Cell Transplantation Verona Italy
| | - L. Flenghi
- Azienda Ospedaliera di Perugia Hematology Perugia Italy
| | - C. Ghiggi
- IRCCS Ospedale Policlinico San Martino Hematology Genova Italy
| | | | - V. Stefoni
- University of Bologna Institute of Hematology "Seràgnoli" Bologna Italy
| | - S. Volpetti
- Presidio Ospedaliero Universitario "Santa Maria della Misericordia” di Udine ASUFC Clinic of Hematology Udine Italy
| | - V. R. Zilioli
- ASST Grande Ospedale Metropolitano Niguarda Division of Hematology Milano Italy
| | - F. Ballerini
- IRCCS Ospedale Policlinico San Martino Clinic of Hematology Genova Italy
| | - R. Bruna
- Ospedale Maggiore Della Carità Division of Hematology Novara Italy
| | - F. Cavallo
- University of Torino Azienda Ospedaliera e Universitaria Città della Salute e della Scienza Division of Hematology Department of Molecular Biotechnologies and Health Sciences Torino Italy
| | - G. Musuraca
- IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori" Division of Hematology Meldola Italy
| | - C. Patti
- Azienda Villa Sofia Cervello Division of Onco‐Hematology Palermo Italy
| | - F. Re
- Azienda Ospedaliera‐Universitaria di Parma Hematology and CTMO Parma Italy
| | - M. Tani
- Ospedale Santa Maria delle Croci Hematology Unit Ravenna Italy
| | - M. Varettoni
- Fondazione IRCCS Policlinico San Matteo Division of Hematology Pavia Italy
| | - M. Zanni
- Azienda Ospedaliera Santi Antonio e Biagio e Cesare Arrigo Division of Hematology Alessandria Italy
| | - A. Dodero
- Fondazione IRCCS Istituto Nazionale dei Tumori di Milano Hematology and Stem Cell Transplantation Milano Italy
| | - S. A. Pileri
- European Institute of Oncology IRCCS Division of Haematopathology Milano Italy
| | - G. Ciccone
- Azienda Ospedaliera e Universitaria Città della Salute e della Scienza and CPO Piemonte Unit of Clinical Epidemiology Torino Italy
| | - P. Corradini
- Chair of Hematology University of Milano Fondazione IRCCS Istituto Nazionale dei Tumori di Milano Division of Hematology and Stem Cell Transplantation Milano Italy
| |
Collapse
|
12
|
Tucci A, Merli F, Fabbri A, Mancuso S, Sartori R, Storti S, Luminari S, Mammi C, Marcheselli L, Arcari A, Cavallo F, Zilioli VR, Bottelli C, Re A, Gini G, Cox MC, Puccini B, Pagani C, Balzarotti M, Spina M, Rossi G. DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) IN LATE‐OCTOGENARIAN (LO) PATIENTS: A SUBSTUDY OF THE “ELDERLY PROJECT” BY THE FONDAZIONE ITALIANA LINFOMI (FIL). Hematol Oncol 2021. [DOI: 10.1002/hon.95_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- A. Tucci
- ASST Spedali Civili Brescia Hematology Division Brescia Italy
| | - F. Merli
- Azienda Unità Sanitaria Locale – IRCCS Hematology Unit Reggio Emilia Italy
| | - A. Fabbri
- zienda Ospedaliera Universitaria Senese and University of Siena Unit of Hematology Siena Italy
| | - S. Mancuso
- Department Pro.Mi.Se Univeristy of Palermo Haematology Division Palermo Italy
| | - R. Sartori
- Veneto Institute of Oncology IOV‐IRCCS Department of Clinical and Experimental Oncology Oncohematology Unit Castelfranco Veneto (TV) Italy
| | - S. Storti
- Università Cattolica Onco‐hematology Unit Campobasso‐Roma Italy
| | - S. Luminari
- University of Modena and Reggio Emilia Azienda Unità Sanitaria Locale – IRCCS Department CHIMOMO Hematology Unit Reggio Emilia Italy
| | - C. Mammi
- Gruppo Amici dell'Ematologia GRADE‐ Onlus Foundation Hematology Unit Reggio Emilia Italy
| | - L. Marcheselli
- Fondazione Italiana Linfomi Onlus Fondazione Italiana Linfomi Onlus Modena Italy
| | - A. Arcari
- Ospedale Guglielmo da Saliceto Hematology Unit Piacenza Italy
| | - F. Cavallo
- University of Torino/AOU “Città della Salute e della Scienza di Torino” Division of Hematology Department of Molecular Biotechnologies and Health Sciences Torino Italy
| | - V. R. Zilioli
- ASST Grande Ospedale Metropolitano Niguarda Division of Hematology Milano Italy
| | - C. Bottelli
- ASST Spedali Civili Brescia Hematology Division Brescia Italy
| | - A. Re
- ASST Spedali Civili Brescia Hematology Division Brescia Italy
| | - G. Gini
- Azienda Ospedaliera Universitaria Ospedali Riuniti Division of Hematology Ancona Italy
| | - M. C. Cox
- Azienda Ospedaliera Universitaria S.Andrea Hematology Unit Roma Italy
| | - B. Puccini
- Careggi University Hospital Hematology Unit Firenze Italy
| | - C. Pagani
- ASST Spedali Civili Brescia Hematology Division Brescia Italy
| | - M. Balzarotti
- Humanitas Clinical Research Hospital‐IRCCS Department of Medical Oncology and Hematology Rozzano (MI) Italy
| | - M. Spina
- Centro di Riferimento Oncologico di Aviano (CRO) IRCCS Division of Medical Oncology and Immune‐related Tumors Aviano (PN) Italy
| | - G. Rossi
- ASST Spedali Civili Brescia Hematology Division Brescia Italy
| |
Collapse
|
13
|
Merli F, Tucci A, Arcari A, Rigacci L, Cavallo F, Cabras G, Alvarez I, Fabbri A, Re A, Ferrero S, Puccini B, Usai SV, Ferrari A, Cencini E, Pennese E, Zilioli VR, Marino D, Balzarotti M, Cox MC, Zanni M, Rocco A, Lleshi A, Botto B, Hohaus S, Merli M, Sartori R, Gini G, Nassi L, Musuraca G, Tani M, Bottelli C, Kovalchuk S, Re F, Flenghi L, Molinari A, Tarantini G, Chimienti E, Marcheselli L, Mammi C, Luminari S, Spina M. THE ELDERLY PROGNOSTIC INDEX (EPI) PREDICTS EARLY MORTALITY IN OLDER PATIENTS WITH DLBCL. A SUBSTUDY OF THE ELDERLY PROJECT BY THE FONDAZIONE ITALIANA LINFOMI (FIL). Hematol Oncol 2021. [DOI: 10.1002/hon.85_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
14
|
Capone L, Cavallo F, Lusini F, Di Minico D, Nardiello B, Leonardo N, Gentile P. PO-1847: ART in prostate cancer: how to use an offline approach with daily CBCT and deformable registration. Radiother Oncol 2020. [DOI: 10.1016/s0167-8140(21)01865-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
15
|
Rovini E, Galperti G, Fiorini L, Mancioppi G, Manera V, Cavallo F. SensRing, a novel wearable ring-shaped device for objective analysis of reachto-grasp movements. Annu Int Conf IEEE Eng Med Biol Soc 2020; 2020:4020-4023. [PMID: 33018881 DOI: 10.1109/embc44109.2020.9176116] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Abstract
Reach-to-grasp actions have been recently studied to highlight how intentions influence action planning and shapes the movement kinematics. Reach-to-grasp (RG) kinematics can reveal important information on motor planning and control in several pathologies, including neurodegenerative diseases. Current methods are mainly based on optoelectronic analysis systems, which provide accurate movement tracking but are expensive, time-consuming, and limited to constrained research-oriented space. In this study, we proposed an innovative, non-invasive, and easy-to-use ringshaped wearable system, named SensRing, able to record inertial data during the movement. To ensure accurate and precise measures, which are mandatory for clinical practice, a preliminary technical validation of the SensRing with respect to the Vicon (i.e., gold standard for motion analysis) was performed on two finger tapping exercises. Preliminary results pointed out very low discrepancies in terms of absolute errors (AbsErr) between the values of repetitions (AbsErr≤0.8), frequency (AbsErr=0.04Hz) and amplitude (AbsErr≤2.7deg) measured by the two systems, as well as high correlation between the measures obtained with the inertial and optical system. Therefore, inertial data from the SensRing were used in a "reach-to-grasp and move" protocol to calculate the performance of a group of healthy young subjects during three RG and move sequences. Particularly, subjects were instructed to reach and grasp a bottle to drink (DRINK), to place it on the table (IND) or to pass it to another partner (SOC). Results showed that SensRing could identify that, in the RG phase, different intentions determine different kinematic parameters of grasping the same object. As concerns the phase of moving, if the movement is different (drink vs IND/SOC) it's easier to find differences between the tasks, but also when the action is the same but with different social intent (IND vs SOC) SensRing found a significant difference.
Collapse
|
16
|
Mancioppi G, Fiorini L, Rovini E, Zeghari R, Gros A, Manera V, Robert P, Cavallo F. How Dominant Hand and Foot Dexterity May Reveal Dementia Onset: A Motor and Cognitive Dual-Task Study .. Annu Int Conf IEEE Eng Med Biol Soc 2020; 2020:5619-5622. [PMID: 33019251 DOI: 10.1109/embc44109.2020.9175854] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
The combined provision of an arising number of dementia cases, and the substantial absence of effective treatments, led the scientific community toward the identification of early phases of this condition. Such an effort aims at the recognition of therapeutic windows and the characterization of the disease's different grades. In the last years, Motor and Cognitive Dual-Tasks (MCDT) have been widely used to address the early diagnosis of several neurocognitive disorders, among which dementia. Here we present different protocols: the walking MCDT, the toe-tapping MCDT, and the forefinger-tapping MCDT. Moreover, each task has been performed under different cognitive conditions: no cognitive effort, counting backwards by 1, 3, and 7. In this work, we report the results obtained through the combination of different motor and cognitive tasks, and we present 2 brand-new MCDT protocols, attempting to identify a sweet-spot for early diagnosis of dementia.
Collapse
|
17
|
Butt AH, Cavallo F, Maremmani C, Rovini E. Biomechanical parameters assessment for the classification of Parkinson Disease using Bidirectional Long Short-Term Memory .. Annu Int Conf IEEE Eng Med Biol Soc 2020; 2020:5761-5764. [PMID: 33019283 DOI: 10.1109/embc44109.2020.9176051] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Nowadays objective and efficient assessment of Parkinson Disease (PD) with machine learning techniques is a major focus for clinical management. This work presents a novel approach for classification of patients with PD (PwPD) and healthy controls (HC) using Bidirectional Long Short-Term Neural Network (BLSTM). In this paper, the SensHand and the SensFoot inertial wearable sensors for upper and lower limbs motion analysis were used to acquire motion data in thirteen tasks derived from the MDS-UPDRS III. Sixty-four PwPD and fifty HC were involved in this study. One hundred ninety extracted spatiotemporal and frequency parameters were applied as a single input against each subject to develop a recurrent BLSTM to discriminate the two groups. The maximum achieved accuracy was 82.4%, with the sensitivity of 92.3% and specificity of 76.2%. The obtained results suggest that the use of the extracted parameters for the development of the BLSTM contributed significantly to the classification of PwPD and HC.
Collapse
|
18
|
Cavallo F, Rovini E, Dolciotti C, Radi L, Ragione RD, Bongioanni P, Fiorini L. Physiological response to Vibro-Acoustic stimulation in healthy subjects: a preliminary study .. Annu Int Conf IEEE Eng Med Biol Soc 2020; 2020:5921-5924. [PMID: 33019322 DOI: 10.1109/embc44109.2020.9175848] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
Over the last decade Vibro-Acoustic Therapy (VAT) was used for several clinical applications. This paper investigates the use of AcusticA®, an innovative VAT solution represented by a wooden chaise longue that follows the construction principles of a "musical instrument that stimulates the whole body" in relation to the sound frequencies produced by the music tracks. Ten healthy young subjects were enrolled for this study. Wearable sensors were used to monitor the human physiological response during the VAT session but also during a traditional acoustic therapy (AT) to highlight similarity and differences of those stimulations. Signals from heart activity, brain activity and electrodermal activity were analyzed to investigate the response during the non-stimulated and the stimulated phases. Additionally, two supervised classification algorithms were used to investigate whether the extracted instances could be grouped into two different groups. The results identify a trend of the attention and meditation features extracted from brain activity, which pointed out the relax efficacy of the VAT.Clinical Relevance - There are not significant differences (p<0.05) in the physiological response between the VAT and the AT stimulation, but during the VAT the alpha coefficients were significant different during the stimulated phase. Finally, the classification algorithms were able to classify the groups with an accuracy equal to 100% in the best case.
Collapse
|
19
|
Rovini E, Moschetti A, Fiorini L, Esposito D, Maremmani C, Cavallo F. Wearable Sensors for Prodromal Motor Assessment of Parkinson's Disease using Supervised Learning. Annu Int Conf IEEE Eng Med Biol Soc 2020; 2019:4318-4321. [PMID: 31946823 DOI: 10.1109/embc.2019.8856804] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
Parkinson's disease (PD) is a common neurodegenerative disorder characterized by disabling motor and non-motor symptoms. Idiopathic hyposmia (IH), a reduced olfactory sensitivity, is a preclinical marker for the pathology and affects >95% of PD patients. In this paper, SensHand V1 and SensFoot V2, two inertial wearable sensors for upper and lower limbs, were developed to acquire motion data in ten tasks of the MDS-UPDRS III. Fifteen healthy subjects of control, 15 IH people, and 15 PD patients were enrolled. Seventy-one parameters per side were computed by spatiotemporal and frequency data analysis, and the most significant were selected to distinguish among the different classes. Performances of supervised learning algorithms (i.e., Support Vector Machine (SVM), and Random Forest (RF)) were compared on two-group and three-group classification and considering upper and lower limbs separately or together as a full system. Excellent results were obtained for healthy vs. patients classification (accuracy 1.00 for RF, and 0.97 for SVM), and good results were achieved by including IH subjects (0.92 F-measure with RF) within a three-group classification. Overall, the best performances were obtained using the full system with an RF classifier. The system is, thus, suitable to support an objective PD diagnosis. Furthermore, combining motion analysis with a validated olfactory screening test, people at risk for PD can be appropriately analyzed, and subtle changes in motor performance that characterize the prodromal phase and the early PD onset can be identified.
Collapse
|
20
|
Coviello L, Cavallo F, Limosani R, Rovini E, Fiorini L. Machine Learning based Physical Human-Robot Interaction for Walking Support of Frail People. Annu Int Conf IEEE Eng Med Biol Soc 2020; 2019:3404-3407. [PMID: 31946610 DOI: 10.1109/embc.2019.8856917] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
In the near future robots will permeate our daily life empowering human beings in several activities of daily living. Particular, service robots could actively support indoor mobility tasks thus to enhance the independent living of citizens. They should be able to provide tailored services to citizens to achieve higher physical human-robot interaction. Too often service robots were designed without taking into account end-users functional requirements, which can change with age and geriatric syndromes. In this paper, we present a robot smart control based on machine learning strategies and adaptable to different handgrip strengths. The smart control was implemented on ASTRO robot conceived to be a companion and to support indoor mobility, among other activities. Particularly, three smart controller strategies were implemented and tested with end users from technical and user point of view. The results show promising results that underline the proposed approach was suitable for the proposed application.
Collapse
|
21
|
Capone L, Lusini F, Cavallo F, Nardiello B, Tolu B, Nicolini L, Gentile P. OC-053: ART in prostate cancer: how to use an offline approach with daily CBCT and deformable registration. Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(20)30442-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
22
|
Riccardo F, Tarone L, Barutello G, Arigoni M, Giacobino D, Iussich S, Occhipinti S, Ferrone S, Buracco P, Cavallo F. Anti-CSPG4 DNA vaccination as a promising strategy for the treatment of CSPG4+ tumours: A comparative oncology trial. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz253.043] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
23
|
Barutello G, Riccardo F, Voena C, Chiarle R, Cavallo F. Maternal immunization against ALK as a weapon to fight neuroblastoma. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz253.045] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
24
|
Vitolo U, Witzig T, Gascoyne R, Scott D, Zhang Q, Jurczak W, Özcan M, Hong X, Zhu J, Jin J, Belada D, Bergua J, Piazza F, Mócikova H, Molinari A, Yoon D, Cavallo F, Tani M, Izutsu K, Kato K, Czuczman M, Hersey S, Kilcoyne A, Russo J, Hudak K, Zhang J, Chiappella A, Nowakowski G. ROBUST: First report of phase III randomized study of lenalidomide/R-CHOP (R2
-CHOP) vs placebo/R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma. Hematol Oncol 2019. [DOI: 10.1002/hon.5_2629] [Citation(s) in RCA: 71] [Impact Index Per Article: 14.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
- U. Vitolo
- Division of Hematology; A.O.U. Città della Salute e della Scienza Hospital and University; Torino Italy
| | - T.E. Witzig
- Division of Hematology; Mayo Clinic; Rochester MN United States
| | - R.D. Gascoyne
- Centre for Lymphoid Cancer; British Columbia Cancer; Vancouver BC Canada
| | - D.W. Scott
- Centre for Lymphoid Cancer; British Columbia Cancer; Vancouver BC Canada
| | - Q. Zhang
- Harbin Medical University Cancer Hospital; Harbin Heilongjiang China
| | - W. Jurczak
- Department of Hematology; Jagiellonian University; Krakow Poland
| | - M. Özcan
- Department of Hematology; Ankara University; Ankara Turkey
| | - X. Hong
- Cancer Hospital; Fudan University; Shanghai China
| | - J. Zhu
- Beijing Cancer Hospital; Beijing China
| | - J. Jin
- The First Affiliated Hospital of Medical School of Zhejiang University; First Hospital of Zhejiang Province; Zhejiang Hangzhou China
| | - D. Belada
- Fourth Department of Internal Medicine-Hematology; Charles University Hospital and Faculty of Medicine; Hradec Králové Czech Republic
| | - J.M. Bergua
- Servicio de Hematologia; Hospital Universitario San Pedro de Alcántara; Cáceres Spain
| | - F. Piazza
- Division of Hematology, Department of Medicine; University of Padova and Azienda Ospedaliera di Padova; Padova Italy
| | - H. Mócikova
- Department of Internal Medicine and Haematology; Faculty Hospital Kralovske Vinohrady; Prague Czech Republic
| | | | - D.H. Yoon
- Department of Oncology, Asan Medical Center; University of Ulsan College of Medicine; Seoul South Korea Republic of Korea
| | - F. Cavallo
- AOU Città della Salute e della Scienza di Torino; Turin Italy
| | - M. Tani
- U.O. Ematologia, Dipartimento Oncologia e Ematologia; Ospedale Santa Maria delle Croci; Ravenna Italy
| | - K. Izutsu
- National Cancer Center Hospital; Tokyo Japan
| | - K. Kato
- Department of Medicine and Biosystemic Science; Kyushu University Faculty of Medicine; Fukuoka City Japan
| | - M. Czuczman
- Clinical Research & Development; Celgene Corporation; Summit NJ USA
| | - S. Hersey
- Clinical Research & Development; Celgene Corporation; Summit NJ USA
| | - A. Kilcoyne
- Clinical Research & Development; Celgene Corporation; Summit NJ USA
| | - J. Russo
- Clinical Research & Development; Celgene Corporation; Summit NJ USA
| | - K. Hudak
- Clinical Research & Development; Celgene Corporation; Summit NJ USA
| | - J. Zhang
- Clinical Research & Development; Celgene Corporation; Summit NJ USA
| | - A. Chiappella
- Division of Hematology; A.O.U. Città della Salute e della Scienza Hospital and University; Torino Italy
| | - G.S. Nowakowski
- Division of Hematology; Mayo Clinic; Rochester MN United States
| | | |
Collapse
|
25
|
Spina M, Merli F, Puccini B, Cavallo F, Cabras M, Fabbri A, Angrilli F, Zilioli V, Marino D, Balzarotti M, Ladetto M, Cox M, Petrucci L, Arcari A, Gini G, Chiappella A, Hohaus S, Musuraca G, Merli M, Sartori R, Nassi L, Tani M, Re F, Flenghi L, Molinari A, Kovalchuk S, Bottelli C, Ferrero S, Dessì D, Cencini E, Pennese E, Marcheselli L, Mammi C, Luminari S, Tucci A. THE ELDERLY PROJECT BY THE FONDAZIONE ITALIANA LINFOMI: A PROSPECTIVE COMPREHENSIVE GERIATRIC ASSESSMENT (CGA) OF 1353 ELDERLY PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA. Hematol Oncol 2019. [DOI: 10.1002/hon.58_2630] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- M. Spina
- Division of Medical Oncology and Immune-related tumors; National Cancer Institute; Aviano (PN) Italy
| | - F. Merli
- Hematology; Azienda USL-IRCCS; Reggio Emilia Italy
| | - B. Puccini
- Hematology Department; University of Florence and AOU Careggi; Firenze Italy
| | - F. Cavallo
- Division of Hematology; University of Torino, Azienda Ospedaliero Universitaria, Città della Salute e della Scienza di Torino; Torino Italy
| | - M.G. Cabras
- Division of Hematology; Ospedale Businco; Cagliari Italy
| | - A. Fabbri
- Unit of Hematology; Azienda Ospedaliera Universitaria Senese; Siena Italy
| | - F. Angrilli
- Lymphoma Unit, Department of Hematology; Ospedale Spirito Santo; Pescara Italy
| | - V.R. Zilioli
- Division of Hematology; ASST Grande Ospedale Metropolitano Niguarda; Milano Italy
| | - D. Marino
- Medical Oncology 1; Veneto Institute of Oncology IOV IRCCS; Padova Italy
| | - M. Balzarotti
- Department of Medical Oncology and Hematology; Humanitas, Clinical and Research Hospital-IRCCS; Rozzano (MI) Italy
| | - M. Ladetto
- Division of Hematology; A.O. SS Antonio e Biagio and Cesare Arrigo; Alessandria Italy
| | - M.C. Cox
- Hematology Unit; AOU Sant'Andrea; Roma Italy
| | - L. Petrucci
- Institute of Hematology; Dept. of Translational and Precision Medicine “Sapienza”, University of Roma; Roma Italy
| | - A. Arcari
- Haematology Unit; Azienda AUSL; Piacenza Italy
| | - G. Gini
- Division of Haematology; Ospedali Riuniti; Ancona Italy
| | - A. Chiappella
- Division of Hematology; Città della Salute e della Scienza Hospital and University; Torino Italy
| | - S. Hohaus
- Catholic University of the Sacred Heart; University Policlinico Gemelli Foundation, IRCCS; Roma Italy
| | - G. Musuraca
- Department of Hematology; Istituto Scientifico Romagnolo Per Lo Studio e La Cura Dei Tumori; Meldola (FC) Italy
| | - M. Merli
- Hematology, Ospedale di Circolo e Fondazione Macchi; University of Insubria; Varese Italy
| | - R. Sartori
- Hematology Department; Castelfranco Veneto Regional Hospital; Castelfranco Veneto (TV) Italy
| | - L. Nassi
- Hematology; AOU Maggiore della Carità; Novara Italy
| | - M. Tani
- Department of Hematology; S. Maria delle Croci Hospital; Ravenna Italy
| | - F. Re
- Hematology and BMT Center; Azienda Ospedaliera, University of Parma; Parma Italy
| | - L. Flenghi
- Hematology; S. Maria della Misericordia Hospital; Perugia Italy
| | - A. Molinari
- Hematology Unit; Infermi Hospital; Rimini Italy
| | - S. Kovalchuk
- Hematology Department; University of Florence and AOU Careggi; Firenze Italy
| | - C. Bottelli
- Department of Hematology; ASST Spedali Civili; Brescia Italy
| | - S. Ferrero
- Division of Hematology; University of Torino, Azienda Ospedaliero Universitaria, Città della Salute e della Scienza di Torino; Torino Italy
| | - D. Dessì
- Division of Hematology; Ospedale Businco; Cagliari Italy
| | - E. Cencini
- Unit of Hematology; Azienda Ospedaliera Universitaria Senese; Siena Italy
| | - E. Pennese
- Lymphoma Unit, Department of Hematology; Ospedale Spirito Santo; Pescara Italy
| | | | - C. Mammi
- GRADE; Gruppo Amici dell'Ematologia Foundation; Reggio Emilia Italy
| | - S. Luminari
- Hematology; Azienda USL-IRCCS; Reggio Emilia Italy
| | - A. Tucci
- Department of Hematology; ASST Spedali Civili; Brescia Italy
| |
Collapse
|
26
|
Kalakonda N, Cavallo F, Follows G, Goy A, Vermaat J, Casasnovas O, Lavee O, Maerevoet M, Zijlstra J, Bakshi S, Bouabdallah R, Choquet S, Gurion R, Hill B, Jaeger U, Sancho J, Schuster M, Thieblemont C, De la Cruz F, Egyed M, Mishra S, Offner F, Vassilakopoulos T, Warzocha K, Oluyadi A, McCarthy D, Ma X, Corona K, Shah J, Van Den Neste E, Canales M. A PHASE 2B STUDY OF SELINEXOR IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL). Hematol Oncol 2019. [DOI: 10.1002/hon.31_2629] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- N. Kalakonda
- Molecular and Clinical Cancer Medicine; University of Liverpool; Liverpool United Kingdom
| | - F. Cavallo
- Molecular Biotechnology and Health Sciences; Aziena Ospedaliero - Universitaria Città della Salute e della Scienza di Torino; Turin Italy
| | - G. Follows
- Haematology; Cambridge University Hospitals NHS Foundation Trust Addenbrooke's Hospital; Cambridge United Kingdom
| | - A. Goy
- Oncology; Hackensack University Medical Center; Hackensack United States
| | - J. Vermaat
- Hematology; Leiden University Medical Center; Leiden Netherlands
| | | | - O. Lavee
- Hematology; St. Vincent's Hospital Sydney; Darlinghurst Australia
| | - M. Maerevoet
- Hematology; Service Hématologie, Institut Bordet; Bruxelles Belgium
| | - J. Zijlstra
- Hematology; Amsterdam UMC; Amsterdam Netherlands
| | - S. Bakshi
- Medical Oncology; Dr. B. R. A. Institute Rotary Cancer Hospital; New Delhi India
| | - R. Bouabdallah
- Oncology/Hematology; Institut Paoli-Calmettes; Marseille France
| | - S. Choquet
- Hematology; Hospital Pitie Salpetriere; Paris France
| | - R. Gurion
- Hematology; Rabin MC; Petah Tiqwa Israel
| | - B. Hill
- Hematology and Medical Oncology; Cleveland Clinic Main Campus; Cleveland United States
| | - U. Jaeger
- Medicine I; Medical University of Vienna; Vienna Austria
| | - J. Sancho
- Clinical Hematology; Hospital Germans Trias i Pujol; Barcelona Spain
| | - M. Schuster
- Medicine; Stony Brook University; Stony Brook United States
| | | | - F. De la Cruz
- Hematology; Hospital Universitario Virgen del Rocío; Sevilla Spain
| | - M. Egyed
- Hematology; Teaching Hospital Mór Kaposi; Kaposvár Hungary
| | - S. Mishra
- Medical Oncology; Institute of Medical Sciences & SUM Hospital; Bhubaneswar India
| | | | | | - K. Warzocha
- Hematology; Instytut Hematologii i Transfuzjologii; Warszawa Poland
| | - A. Oluyadi
- Clinical Development; Karyopharm Therapeutics Inc.; Newton United States
| | - D. McCarthy
- Clinical Operations; Karyopharm Therapeutics Inc.; Newton United States
| | - X. Ma
- Biostatistics; Karyopharm Therapeutics Inc.; Newton United States
| | - K. Corona
- Medical Affairs; Karyopharm Therapeutics Inc.; Newton United States
| | - J. Shah
- Clinical Development; Karyopharm Therapeutics Inc.; Newton United States
| | - E. Van Den Neste
- Hematology; Cliniques Universitaires Saint-Luc; Brussels Belgium
| | - M. Canales
- Medicine; Hospital Universitario La Paz; Madrid Spain
| |
Collapse
|
27
|
Balzarotti M, Ricardi U, Spina M, Monagheddu C, Tucci A, Cavallo F, Zanni M, Arcari A, Rusconi C, Sartori R, Merli F, Re F, Vitolo U, Dessi D, Melis L, Gaidano G, Chiti A, Deidda M, Santoro A, Ciccone G, Chauvie S, Cabras M. PET-DRIVEN RADIOTHERAPY IN PATIENTS WITH LOW RISK DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): THE DLCL10 MULTICENTER PHASE 2 TRIAL BY FONDAZIONE ITALIANA LINFOMI (FIL). Hematol Oncol 2019. [DOI: 10.1002/hon.62_2630] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- M. Balzarotti
- Medical Oncology and Hematology; Humanitas Clinical and Research Hospital-IRCCS-Humanitas University; Rozzano Milano Italy
| | - U. Ricardi
- Radiotherapy; AOU Città della Salute e della Scienza, University of Torino; Torino Italy
| | - M. Spina
- Medical Oncology; IRCCS CRO; Aviano (PN) Italy
| | - C. Monagheddu
- Epidemiologia Clinica e Valutativa; AOU Città della Salute e della Scienza e CPO; Torino Italy
| | - A. Tucci
- Hematology; Spedali Civili; Brescia
| | - F. Cavallo
- Hematology; Universita' Citta' della Salute e della Scienza; Torino Italy
| | - M. Zanni
- Hematology; ASO ss Antonio e Biagio e Arrigo; Alessandria Italy
| | - A. Arcari
- Hematology; Ospedale Guglielmo da Saliceto; Piacenza Italy
| | - C. Rusconi
- Hemtaology; ASST Grande Ospedale Metropolitano Niguarda; Milano Italy
| | - R. Sartori
- Hematology; Azienda ULSS 2 Marca Trevigiana; Castelfranco Veneto Treviso Italy
| | - F. Merli
- Hematology; Arcispedale Santa Maria Nuova; Reggio Emilia Italy
| | - F. Re
- Hematology; AOU Parma; Parma Italy
| | - U. Vitolo
- Hematology; AO Città della Salute e della Scienza; Torino Italy
| | - D. Dessi
- Hematology; Ospedale Oncologico Armando Businco; Cagliari Italy
| | - L. Melis
- Nuclear Medicine; Ospedale Oncologico Armando Businco; Cagliari Italy
| | - G. Gaidano
- Hematology; AOU Maggiore della Carità di Novara; Novara Italy
| | - A. Chiti
- Nuclear Medicine; Humanitas Clinical and Research Hospital-IRCCS - Humanitas University; Rozzano Milano Italy
| | - M. Deidda
- Radiotherapy; Ospedale Oncologico Armando Businco; Cagliari Italy
| | - A. Santoro
- Medical Oncology and Hematology; Humanitas Clinical and Research Hospital-IRCCS-Humanitas University; Rozzano Milano Italy
| | - G. Ciccone
- Epidemiologia Clinica e Valutativa; AOU Città della Salute e della Scienza e CPO; Torino Italy
| | - S. Chauvie
- Medical Physics; Santa Croce e Carle Hospital; Cuneo Italy
| | - M. Cabras
- Hematology; Ospedale Oncologico Armando Businco; Cagliari Italy
| |
Collapse
|
28
|
Federico M, Mannina D, Versari A, Ferrero S, Marcheselli L, Boccomini C, Dondi A, Tucci A, Guerra L, Galimberti S, Cavallo F, Olivieri J, Corradini P, Arcaini L, Chauvie S, Del Giudice I, Rusconi C, Pinto A, Molinari A, Pulsoni A, Merli M, Kovalchuk S, Nassi L, Bolis S, Gattei V, Manni M, Pileri S, Brugiatelli M, Luminari S. RESPONSE ORIENTED MAINTENANCE THERAPY IN ADVANCED FOLLICULAR LYMPHOMA. RESULTS OF THE INTERIM ANALYSIS OF THE FOLL12 TRIAL CONDUCTED BY THE FONDAZIONE ITALIANA LINFOMI. Hematol Oncol 2019. [DOI: 10.1002/hon.110_2629] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- M. Federico
- Dipartimento Chirurgico, Medico, Odontoiatrico e di Scienze Morfologiche; University of Modena and Reggio Emilia; Modena Italy
| | - D. Mannina
- UOC di Ematologia; Azienda Ospedaliera Papardo; Messina Italy
| | - A. Versari
- Nuclear Medicine Unit; AUSL-IRCCS of Reggio Emilia; Reggio Emilia Italy
| | - S. Ferrero
- Department of Molecular Biotechnologies and Health Sciences, Division of Hematology; University of Torino; Torino Italy
| | - L. Marcheselli
- Dipartimento di Scienze Mediche e Chirurgiche Materno-Infantili e dell'Adulto; Fondazione Italiana Linfomi; Modena Italy
| | - C. Boccomini
- SC Ematologia; AOU Città della Salute e della Scienza di Torino; Torino Italy
| | - A. Dondi
- Dipartimento di Scienze Mediche e Chirurgiche Materno-Infantili e dell'Adulto; Fondazione Italiana Linfomi; Modena Italy
| | - A. Tucci
- SC Ematologia; ASST-Spedali Civili; Brescia Italy
| | - L. Guerra
- Nuclear Medicine Unit; San Gerardo Hospital; Monza Italy
| | - S. Galimberti
- Division of Hematology, Department of Oncology; Santa Chiara Hospital; Pisa Italy
| | - F. Cavallo
- Division of Hematology; University of Torino, Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino; Torino Italy
| | - J. Olivieri
- Clinica Ematologica; Centro Trapianti e Terapie Cellulari “C. Melzi”, DAME, ASUI; Udine Italy
| | - P. Corradini
- Department of Oncology and Hematology; Fondazione Istituto Nazionale dei Tumori Milano University of Milano; Milano Italy
| | - L. Arcaini
- Department of Molecular Medicine; University of Pavia, Division of Hematology, Fondazione IRCCS Policlinico S. Matteo; Pavia Italy
| | - S. Chauvie
- Medical Physics Unit; Azienda Ospedaliera S. Croce e Carle; Cuneo Italy
| | - I. Del Giudice
- Hematology Unit, Department of Translational and Precision Medicine; Sapienza University of Rome; Roma Italy
| | - C. Rusconi
- Division of Hematology; ASST Grande ospedale Metropolitano Niguarda; Milano Italy
| | - A. Pinto
- Department of Hematology and Developmental Therapeutics; Istituto Nazionale Tumori, Fondazione ‘G. Pascale’ IRCCS; Napoli Italy
| | - A. Molinari
- UO Ematologia; OC Rimini AUSL Romagna; Rimini Italy
| | - A. Pulsoni
- Hematology Unit, Department of Translational and Precision Medicine; Sapienza University of Rome; Roma Italy
| | - M. Merli
- Hematology; University Hospital "Ospedale di Circolo e Fondazione Macchi" - ASST Sette Laghi, University of Insubria; Varese Italy
| | - S. Kovalchuk
- Ematologia; Università degli Studi di Firenze; Firenze Italy
| | - L. Nassi
- Hematology; AOU Maggiore della Carità; Novara Italy
| | - S. Bolis
- Hematolgy Unit; ASST-Monza; Monza Italy
| | - V. Gattei
- Clinical and Experimental Onco-Haematology Unit; Centro di Riferimento Oncologico, IRCCS; Aviano Italy
| | - M. Manni
- Dipartimento Chirurgico, Medico, Odontoiatrico e di Scienze Morfologiche; University of Modena and Reggio Emilia; Modena Italy
| | - S. Pileri
- Divisione di Diagnosi Ematopatologica; Istituto Europeo di Oncologia; Milano Italy
| | - M. Brugiatelli
- UOC di Ematologia; Azienda Ospedaliera Papardo; Messina Italy
| | - S. Luminari
- S.C. Ematologia; Arcispedale S. Maria Nuova-IRCCS; Reggio Emilia Italy
| |
Collapse
|
29
|
Chiappella A, Carniti C, Evangelista A, Re A, Cabras M, Stefoni V, Castellino C, Congiu A, Pinto A, Zanni M, Rusconi C, Molinari A, Ciancia R, Baldini L, Nassi L, Re F, Tani M, Ilariucci F, Cavallo F, Santoro A, Volpetti S, Dodero A, Pileri S, Ciccone G, Corradini P. PHASE II FIL-PTCL13 STUDY OF ROMIDEPSIN-CHOEP FOLLOWED BY HIGH-DOSE CHEMOTHERAPY AND TRANSPLANTATION IN UNTREATED PERIPHERAL T-CELL LYMPHOMAS. Hematol Oncol 2019. [DOI: 10.1002/hon.3_2632] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- A. Chiappella
- Ematologia; AOU Città della Salute e della Scienza di Torino; Torino Italy
| | - C. Carniti
- Ematologia; Università degli Studi di Milano; Milano Italy
| | - A. Evangelista
- SSD Epidemiologia Clinica e Valutativa; Clinical Trial Center, AOU Città della Salute e della Scienza di Torino e CPO Piemonte; Torino Italy
| | - A. Re
- Ematologia; ASTT Spedali Civili di Brescia; Brescia Italy
| | - M.G. Cabras
- Ematologia; Ospedale Oncologico Armando Businco; Cagliari Italy
| | - V. Stefoni
- Ematologia; Policlinico S.Orsola-Malpighi, Istituto di Ematologia "Seragnoli"; Bologna Italy
| | - C. Castellino
- Ematologia e Trapianto di Midollo Osseo; AO Santa Croce e Carle; Cuneo Italy
| | - A.G. Congiu
- Ematologia; Ospedale Policlinico San Martino S.S.R.L. - IRCCS per l'Oncologia; Genova Italy
| | - A. Pinto
- Ematologia Oncologica; Istituto Nazionale Tumori - IRCCS Fondazione G. Pascale; Napoli Italy
| | - M. Zanni
- Ematologia; AO SS Antonio e Biagio e Cesare Arrigo; Alessandria Italy
| | - C. Rusconi
- Ematologia; ASST Grande Ospedale Metropolitano Niguarda; Milano Italy
| | | | - R. Ciancia
- Oncoematologia; trapianti emopoietici e terapie cellulari, Centro di Riferimento Oncologico CRO, IRCCS; Aviano Italy
| | - L. Baldini
- Ematologia; Ospedale Maggiore Policlinico - Fondazione IRCCS Ca' Granda; Milano Italy
| | - L. Nassi
- Ematologia; AOU Maggiore della Carità di Novara; Novara Italy
| | - F. Re
- Ematologia e CTMO; AOU Ospedale Maggiore di Parma; Parma Italy
| | - M. Tani
- Ematologia; Ospedale Santa Maria delle Croci; Ravenna Italy
| | - F. Ilariucci
- Ematologia; Azienda Ospedaliera Arcispedale Santa Maria Nuova - IRCCS; Reggio Emilia Italy
| | - F. Cavallo
- Ematologia; Università degli Studi - AOU Città della Salute e della Scienza di Torino; Torino Italy
| | - A. Santoro
- Ematologia; Istituto Clinico Humanitas; Rozzano Italy
| | - S. Volpetti
- Ematologia; ASUI Santa Maria della Misericordia; Udine Italy
| | - A. Dodero
- Ematologia; Fondazione IRCCS Istituto Nazionale dei Tumori; Milano Italy
| | - S.A. Pileri
- Emopatologia; Istituto Europeo Oncologico IRCCS; Milano Italy
| | - G. Ciccone
- SSD Epidemiologia Clinica e Valutativa; Clinical Trial Center, AOU Città della Salute e della Scienza di Torino e CPO Piemonte; Torino Italy
| | - P. Corradini
- Ematologia; Fondazione IRCCS Istituto Nazionale dei Tumori - Università degli Studi di Milano; Milano Italy
| |
Collapse
|
30
|
Rovini E, Fiorini L, Esposito D, Maremmani C, Cavallo F. Fine Motor Assessment With Unsupervised Learning For Personalized Rehabilitation in Parkinson Disease. IEEE Int Conf Rehabil Robot 2019; 2019:1167-1172. [PMID: 31374787 DOI: 10.1109/icorr.2019.8779543] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/10/2023]
Abstract
Parkinson disease (PD) is a common neurodegenerative disorders characterized by motor and non-motor impairments. Since the quality of life of PD patients becomes poor while pathology develops, it is imperative to improve the identification of personalized rehabilitation and treatments approaches based on the level of the neurodegeneration process. Objective and precise assessment of the severity of the pathology is crucial to identify the most appropriate treatments. In this context, this paper proposes a wearable system able to measure the motor performance of PD subjects. Two inertial devices were used to capture the motion of the lower and upper limbs respectively, while performing six motor tasks. Forty-one kinematic features were extracted from the inertial signals to describe the performance of each subjects. Three unsupervised learning algorithms (k-Means, Self-organizing maps (SOM) and hierarchical clustering) were applied with a blind approach to group the motor performance. The results show that SOM was the best classifier since it reached accuracy equal to 0.950 to group the instances in two classes (mild vs advanced), and 0.817 considering three classes (mild vs moderate vs severe). Therefore, this system enabled objective assessment of the PD severity through motion analysis, allowing the evaluation of residual motor capabilities and fostering personalized paths for PD rehabilitation and assistance.
Collapse
|
31
|
Butt AH, Rovini E, Dolciotti C, De Petris G, Bongioanni P, Carboncini MC, Cavallo F. Objective and automatic classification of Parkinson disease with Leap Motion controller. Biomed Eng Online 2018; 17:168. [PMID: 30419916 PMCID: PMC6233603 DOI: 10.1186/s12938-018-0600-7] [Citation(s) in RCA: 34] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2018] [Accepted: 11/01/2018] [Indexed: 11/10/2022] Open
Abstract
Background The main objective of this paper is to develop and test the ability of the Leap Motion controller (LMC) to assess the motor dysfunction in patients with Parkinson disease (PwPD) based on the MDS-UPDRSIII exercises. Four exercises (thumb forefinger tapping, hand opening/closing, pronation/supination, postural tremor) were used to evaluate the characteristics described in MDS-UPDRSIII. Clinical ratings according to the MDS/UPDRS-section III items were used as target. For that purpose, 16 participants with PD and 12 healthy people were recruited in Ospedale Cisanello, Pisa, Italy. The participants performed standardized hand movements with camera-based marker. Time and frequency domain features related to velocity, angle, amplitude, and frequency were derived from the LMC data. Results Different machine learning techniques were used to classify the PD and healthy subjects by comparing the subjective scale given by neurologists against the predicted diagnosis from the machine learning classifiers. Feature selection methods were used to choose the most significant features. Logistic regression (LR), naive Bayes (NB), and support vector machine (SVM) were trained with tenfold cross validation with selected features. The maximum obtained classification accuracy with LR was 70.37%; the average area under the ROC curve (AUC) was 0.831. The obtained classification accuracy with NB was 81.4%, with AUC of 0.811. The obtained classification accuracy with SVM was 74.07%, with AUC of 0.675. Conclusions Results revealed that the system did not return clinically meaningful data for measuring postural tremor in PwPD. In addition, it showed limited potential to measure the forearm pronation/supination. In contrast, for finger tapping and hand opening/closing, the derived parameters showed statistical and clinical significance. Future studies should continue to validate the LMC as updated versions of the software are developed. The obtained results support the fact that most of the set of selected features contributed significantly to classify the PwPD and healthy subjects.
Collapse
Affiliation(s)
- A H Butt
- BioRobotics Institute, Scuola Superiore Sant'Anna, Pontedera, Italy
| | - E Rovini
- BioRobotics Institute, Scuola Superiore Sant'Anna, Pontedera, Italy
| | - C Dolciotti
- Institute of Information Science and Technologies National Research Council, Pisa, Italy
| | - G De Petris
- Telecom Italia, WHITE Lab (Wellbeing and Health Innovative Technologies Lab), Pisa, Italy
| | - P Bongioanni
- Severe Acquired Brain Injuries Department Section, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy.,Neurocare Onlus, Pisa, Italy
| | - M C Carboncini
- Severe Acquired Brain Injuries Department Section, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy
| | - F Cavallo
- BioRobotics Institute, Scuola Superiore Sant'Anna, Pontedera, Italy.
| |
Collapse
|
32
|
Levis M, De Luca V, Bartoncini S, Botto B, Giorgi M, Chiappella A, Ferrero S, Fava A, Cavallo F, Caracciolo D, Vicentini S, Gastino A, Furfaro G, Priolo G, Pregno P, Filippi A, Vitolo U, Orsucci L, Ricardi U. A Prospective, Observational Study Evaluating Early Subclinical Cardiotoxicity with Global Longitudinal Strain Imaging in Lymphoma Patients Treated with Chemotherapy +/- Mediastinal Radiation Therapy: The CARDIOCARE Project. Int J Radiat Oncol Biol Phys 2018. [DOI: 10.1016/j.ijrobp.2018.06.230] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
33
|
Jones S, Angiouli S, Gerding K, Keefer L, Hernandez J, White J, Simmons J, Cavallo F, Sausen M. P3.13-25 Development of a Comprehensive Genomic Profiling System to Detect Actionable Genetic Alterations and Tumor Mutation Burden. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.1866] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
34
|
Butt AH, Rovini E, Dolciotti C, Bongioanni P, De Petris G, Cavallo F. Leap motion evaluation for assessment of upper limb motor skills in Parkinson's disease. IEEE Int Conf Rehabil Robot 2018; 2017:116-121. [PMID: 28813804 DOI: 10.1109/icorr.2017.8009232] [Citation(s) in RCA: 31] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
The main goal of this study is to investigate the potential of the Leap Motion Controller (LMC) for the objective assessment of motor dysfunctioning in patients with Parkinson's disease (PwPD). The most relevant clinical signs in Parkinson's Disease (PD), such as slowness of movements, frequency variation, amplitude variation, and speed, were extracted from the recorded LMC data. Data were clinically quantified using the LMC software development kit (SDK). In this study, 16 PwPD subjects and 12 control healthy subjects were involved. A neurologist assessed the subjects during the task execution, assigning them a score according to the MDS/UPDRS-Section III items. Features of motor performance from both subject groups (patients and healthy controls) were extracted with dedicated algorithms. Furthermore, to find out the significance of such features from the clinical point of view, machine learning based methods were used. Overall, our findings showed the moderate potential of LMC to extract the motor performance of PwPD.
Collapse
|
35
|
Santarelli L, Diyakonova O, Betti S, Esposito D, Castro E, Cavallo F. Development of a Novel Wearable Ring-Shaped Biosensor. Annu Int Conf IEEE Eng Med Biol Soc 2018; 2018:3750-3753. [PMID: 30441182 DOI: 10.1109/embc.2018.8513330] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/09/2023]
Abstract
We report on the preliminary results obtained out of a wearable module designed to be encompassed within a ring-shaped system aimed at providing healthcare services. The module is composed of two sensors for the measuring of Galvanic Skin Response (GSR) and Heart Rate Variability (HRV). A first device validation was carried out by involving four subjects who were asked to perform tasks providing different stress-related statuses. A comparison of physiological parameters measured by the module with those measured by a commercial HRV-GSR sensor chosen as gold standard was made. Two out of the three HRV parameters and all of the GSR parameters measured with the module resulted consistent (mostly differing less than 10%) with the same parameters measured by the gold standard. The work reported in this paper set a milestone for the realization of a system exploiting sensor fusion to provide active ageing, stress detection, activity recognition and e-health services has been achieved.
Collapse
|
36
|
Migliaretti G, Ditaranto S, Guiot C, Vannelli S, Matarazzo P, Cappello N, Stura I, Cavallo F. Long-term response to recombinant human growth hormone treatment: a new predictive mathematical method. J Endocrinol Invest 2018; 41:839-848. [PMID: 29318462 DOI: 10.1007/s40618-017-0816-6] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/28/2017] [Accepted: 12/24/2017] [Indexed: 10/18/2022]
Abstract
INTRODUCTION Recombinant GH has been offered to GH-deficient (GHD) subjects for more than 30 years, in order to improve height and growth velocity in children and to enhance metabolic effects in adults. AIM The aim of our work is to describe the long-term effect of rhGH treatment in GHD pediatric patients, suggesting a growth prediction model. MATERIAL AND METHODS A homogeneous database is defined for diagnosis and treatment modalities, based on GHD patients afferent to Hospital Regina Margherita in Turin (Italy). In this study, 232 GHD patients are selected (204 idiopathic GHD and 28 organic GHD). Each measure is shown in terms of mean with relative standard deviations (SD) and 95% confidence interval (95% CI). To estimate the final height of each patient on the basis of few measures, a mathematical growth prediction model [based on Gompertzian function and a mixed method based on the radial basis functions (RBFs) and the particle swarm optimization (PSO) models] was performed. RESULTS The results seem to highlight the benefits of an early start of treatment, further confirming what is suggested by the literature. Generally, the RBF-PSO method shows a good reliability in the prediction of the final height. Indeed, RMSE is always lower than 4, i.e., in average the forecast will differ at most of 4 cm to the real value. CONCLUSIONS In conclusion, the large and accurate database of Italian GHD patients allowed us to assess the rhGH treatment efficacy and compare the results with those obtained in other Countries. Moreover, we proposed and validated a new mathematical model forecasting the expected final height after therapy which was validated on our cohort.
Collapse
Affiliation(s)
- G Migliaretti
- Depth of Public Health and Pediatric Sciences, University of Turin, Turin, Italy.
| | - S Ditaranto
- Depth of Public Health and Pediatric Sciences, University of Turin, Turin, Italy
| | - C Guiot
- Depth of Neurosciences, University of Turin, Turin, Italy
| | - S Vannelli
- Pediatric Endocrinology, Regina Margherita Children Hospital, University of Turin, Turin, Italy
| | - P Matarazzo
- Pediatric Endocrinology, Regina Margherita Children Hospital, University of Turin, Turin, Italy
| | - N Cappello
- Depth of Public Health and Pediatric Sciences, University of Turin, Turin, Italy
| | - I Stura
- Depth of Public Health and Pediatric Sciences, University of Turin, Turin, Italy
| | - F Cavallo
- Depth of Public Health and Pediatric Sciences, University of Turin, Turin, Italy
| |
Collapse
|
37
|
Maselli M, Fiorini L, Castro E, Baldoli I, Tocchini S, Sportiello MT, Cavallo F, Cecchi F, Laschi C. Development and testing of a new cognitive technological tool for episodic memory: A feasibility study. Annu Int Conf IEEE Eng Med Biol Soc 2018; 2017:893-896. [PMID: 29060016 DOI: 10.1109/embc.2017.8036968] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Cognitive Rehabilitation Therapy refers to any systemic therapy specifically designed to enhance cognitive performance. Recent studies have shown that physical exercise is beneficial for cognitive activity in patients with degenerative diseases. Therefore, the objective of the present study is to provide training for cognitive functions that take advantage of the physical activity in the execution of the task. A feasibility study concerning the application of a new bioengineering technique in cognitive rehabilitation is presented and it divided into two parts. The first one aims at developing a new cognitive tool, called SmartTapestry (ST), for motor and cognitive rehabilitation. The second part aims at understanding its technical viability and its level of sensitivity in measuring the same cognitive domains covered by the standardized tests. The hypothesis of this study is that, despite the introduction of this new variable, the proposed system has the same sensitivity of the traditional tests. The results suggest a good correlation between the two approaches and that SmartTapestry can train the same cognitive functions of traditional cognitive tasks.
Collapse
|
38
|
Fiorini L, Maselli M, Castro E, Tocchini S, Sportiello MT, Laschi C, Cecchi F, Cavallo F. Feasibility study on the assessment of auditory sustained attention through walking motor parameters in mild cognitive impairments and healthy subjects. Annu Int Conf IEEE Eng Med Biol Soc 2018; 2017:897-900. [PMID: 29060017 DOI: 10.1109/embc.2017.8036969] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Dementia and other cognitive disorders affect more than 35 million people worldwide. Over the last years, cognitive training tools were used to improve the brain functioning, thus to slow down the cognitive decline. Recently, research studies have demonstrated that aerobic exercise could play an important restorative role toward cognitive impairments. Therefore, the aim of this work is to present an innovative sensorized approach which combines aerobic exercise and traditional cognitive tools for daily training.
Collapse
|
39
|
Maremmani C, Cavallo F, Purcaro C, Rossi G, Salvadori S, Rovini E, Esposito D, Pieroni A, Ramat S, Vanni P, Fattori B, Meco G. Combining olfactory test and motion analysis sensors in Parkinson's disease preclinical diagnosis: a pilot study. Acta Neurol Scand 2018; 137:204-211. [PMID: 29082509 DOI: 10.1111/ane.12862] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/06/2017] [Indexed: 12/31/2022]
Abstract
OBJECTIVES Preclinical diagnosis of Parkinson's disease (PD) is nowadays a topic of interest as the neuropathological process could begin years before the appearance of motor symptoms. Several symptoms, among them hyposmia, could precede motor features in PD. In the preclinical phase of PD, a subclinical reduction in motor skills is highly likely. In this pilot study, we investigate a step-by-step method to achieve preclinical PD diagnosis. MATERIAL AND METHODS We used the IOIT (Italian Olfactory Identification Test) to screen a population of healthy subjects. We identified 20 subjects with idiopathic hyposmia. Hyposmic subjects underwent an evaluation of motor skills, at baseline and after 1 year, using motion analysis sensors previously created by us. RESULTS One subject showed significant worsening in motor measurements. In this subject, we further conducted a dopaminergic challenge test monitored with the same sensors and, finally, he underwent [123 I]-FP/CIT (DaTscan) SPECT brain imaging. The results show that he is probably affected by preclinical PD. CONCLUSIONS Our pilot study suggests that the combined use of an olfactory test and motor sensors for motion analysis could be useful for a screening of healthy subjects to identify those at a high risk of developing PD.
Collapse
Affiliation(s)
- C. Maremmani
- Unità Operativa di Neurologia, Ospedale delle Apuane Azienda USL Toscana Nord Ovest Massa Italy
| | - F. Cavallo
- Istituto di Biorobotica Scuola Superiore Sant'Anna Pisa Italy
| | - C. Purcaro
- Dipartimento di Neurologia e Psichiatria, e Centro di Ricerca per le Malattie Sociali (CIMS) “Sapienza” Università degli Studi di Roma Roma Italy
| | - G. Rossi
- Unità di Epidemiologia e Biostatistica Istituto di Fisiologia Clinica Consiglio Nazionale delle Ricerche Area della Ricerca di Pisa Pisa Italy
| | - S. Salvadori
- Unità di Epidemiologia e Biostatistica Istituto di Fisiologia Clinica Consiglio Nazionale delle Ricerche Area della Ricerca di Pisa Pisa Italy
| | - E. Rovini
- Istituto di Biorobotica Scuola Superiore Sant'Anna Pisa Italy
| | - D. Esposito
- Istituto di Biorobotica Scuola Superiore Sant'Anna Pisa Italy
| | - A. Pieroni
- Educazione alla Salute Azienda USL Toscana Nord Ovest Carrara Italy
| | - S. Ramat
- Dipartimento di Neuroscienze Azienda Ospedaliero Universitaria Careggi Firenze Italy
| | - P. Vanni
- Unità Operativa di Neurologia Ospedale Santa Maria Annunziata, Azienda USL Toscana Centro Firenze Italy
| | - B. Fattori
- Unità di Audiologia e Foniatria Medicina Interna e Sperimentale Università degli Studi di Pisa Pisa Italy
| | - G. Meco
- Dipartimento di Neurologia e Psichiatria, e Centro di Ricerca per le Malattie Sociali (CIMS) “Sapienza” Università degli Studi di Roma Roma Italy
- NCL [Neurological Centre of Latium (Gruppo NEUROMED)] Centro Studi Clinici Malattia di Parkinson Roma Italy
| |
Collapse
|
40
|
Klanova M, Sehn L, Bence-Bruckler I, Cavallo F, Jin J, Martelli M, Stewart D, Vitolo U, Zaja F, Zhang Q, Mattiello F, Oestergaard M, Fingerle-Rowson G, Nielsen T, Trneny M. CELL OF ORIGIN COMBINED WITH CNS INTERNATIONAL PROGNOSTIC INDEX IMPROVES IDENTIFICATION OF DLBCL PATIENTS WITH HIGH CNS RELAPSE RISK AFTER INITIAL IMMUNOCHEMOTHERAPY. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_25] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- M. Klanova
- 1st Department of Medicine, Charles University General Hospital; Prague, Czech Republic and Pharma Development Clinical Oncology, F. Hoffmann-La Roche Ltd.; Basel Switzerland
| | - L.H. Sehn
- Centre for Lymphoid Cancer; British Columbia Cancer Agency; Vancouver Canada
| | - I. Bence-Bruckler
- Ottawa Hospital Research Institute; The Ottawa Hospital; Ottawa Canada
| | - F. Cavallo
- Ematologia 1; A.O. Universitaria S. Giovanni Battista-Molinette Di Torino; Torino Italy
| | - J. Jin
- The First Affiliated Hospital of College of Medicine; Zhejiang University; Wenzhou China
| | - M. Martelli
- Department of Cellular Biotechnologies and Hematology; Sapienza University; Rome Italy
| | - D. Stewart
- Department of Oncology; Tom Baker Cancer Centre; Calgary Canada
| | - U. Vitolo
- S.C. Ematologia; A.O.U. Citta' Della Salute e della Scienza P.O. Molinette; Turino Italy
| | - F. Zaja
- Oncologia; Clinica Ematologica, ASUI UD S.M. Misericordia di Udine; Udine Italy
| | - Q. Zhang
- Department of Medical Oncology; Harbin Medical University Cancer Hospital; Harbin China
| | - F. Mattiello
- Pharma Development Biometrics Biostatistics; F. Hoffmann-La Roche Ltd.; Basel Switzerland
| | - M.Z. Oestergaard
- Oncology Biomarker Development; F. Hoffmann-La Roche Ltd.; Basel Switzerland
| | - G.R. Fingerle-Rowson
- Pharma Development Clinical Oncology; F. Hoffmann-La Roche Ltd.; Basel Switzerland
| | - T. Nielsen
- Pharma Development Clinical Oncology; F. Hoffmann-La Roche Ltd.; Basel Switzerland
| | - M. Trneny
- 1st Department of Medicine; Charles University General Hospital; Prague Czech Republic
| |
Collapse
|
41
|
Ferrero S, Genuardi E, Klous P, Drandi D, Mantoan B, Monitillo L, Barbero D, Yilmaz M, Cattellino F, Vasta M, Cavallo F, Cortelazzo S, Vitolo U, Luminari S, Federico M, Boccadoro M, Splinter E, Ladetto M. NOVEL MOLECULAR MARKERS FOR MINIMAL RESIDUAL DISEASE (MRD) MONITORING IN MANTLE CELL AND FOLLICULAR LYMPHOMA: THE TARGETED LOCUS AMPLIFICATION (TLA) NGS STRATEGY. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_3] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- S. Ferrero
- Department of Molecular Biotechnology and Health Sciences; University of Torino; Torino Italy
| | - E. Genuardi
- Department of Molecular Biotechnology and Health Sciences; University of Torino; Torino Italy
| | - P. Klous
- B.V., Cergentis B.V.; Utrecht Netherlands
| | - D. Drandi
- Department of Molecular Biotechnology and Health Sciences; University of Torino; Torino Italy
| | - B. Mantoan
- Department of Molecular Biotechnology and Health Sciences; University of Torino; Torino Italy
| | - L. Monitillo
- Department of Molecular Biotechnology and Health Sciences; University of Torino; Torino Italy
| | - D. Barbero
- Department of Molecular Biotechnology and Health Sciences; University of Torino; Torino Italy
| | - M. Yilmaz
- B.V., Cergentis B.V.; Utrecht Netherlands
| | - F. Cattellino
- Department of Molecular Biotechnology and Health Sciences; University of Torino; Torino Italy
| | - M. Vasta
- Department of Molecular Biotechnology and Health Sciences; University of Torino; Torino Italy
| | - F. Cavallo
- Department of Molecular Biotechnology and Health Sciences; University of Torino; Torino Italy
| | - S. Cortelazzo
- Oncology Unit; Humanitas/Gavazzeni Clinic; Bergamo Italy
| | - U. Vitolo
- Department of Oncology, Division of Hematology; AOU Città della Salute e della Scienza di Torino; Torino Italy
| | - S. Luminari
- Clinics and Public Health, “Arcispedale S.Maria Nuova”; University of Modena e Reggio Emilia, Hematology Division, Department of Diagnostic Medicine; Reggio Emilia Italy
| | - M. Federico
- Department of Diagnostic, Clinical and Public Health Medicine; University of Modena and Reggio Emilia; Modena Italy
| | - M. Boccadoro
- Department of Molecular Biotechnology and Health Sciences; University of Torino; Torino Italy
| | | | - M. Ladetto
- Division of Hematology; Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo; Alessandria Italy
| |
Collapse
|
42
|
Merli F, Luminari S, Salvi F, Cavallo F, Gini G, Musuraca G, Gaidano G, Cellini C, Merli M, Ferrari A, Molinari A, Liberati A, Conconi A, Matteucci P, Pozzi S, Musso M, Mammi C, Monaco F, Ferrero S, Tucci A. OBINUTUZUMAB-MINICHOP FOR THE TREATMENT OF ELDERLY UNFIT PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA. A STUDY OF THE FONDAZIONE ITALIANA LINFOMI. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_44] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- F. Merli
- Hematology; Arcispedale Santa Maria Nuova-IRCCS; Reggio Emilia Italy
| | - S. Luminari
- Hematology; Arcispedale Santa Maria Nuova-IRCCS and University of Modena and Reggio Emilia; Reggio Emilia Italy
| | - F. Salvi
- Hematology Unit; Antonio e Biagio e Cesare Arrigo Hospital; Alessandria Italy
| | - F. Cavallo
- Division of Hematology; University of Torino; Torino Italy
| | - G. Gini
- Division of Hematology; Ospedali Riuniti; Ancona Italy
| | - G. Musuraca
- Hematology Unit; Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS; Meldola (FC) Italy
| | - G. Gaidano
- Division of Hematology, Department of Translational Medicine; Amedeo Avogadro University of Eastern Piedmont; Novara Italy
| | - C. Cellini
- Hematology Unit; Santa Maria delle Croci Hospital; Ravenna Italy
| | - M. Merli
- Division of Hematology; University Hospital “Ospedale di Circolo e Fondazione Macchi-ASST Sette Laghi”; Varese Italy
| | - A. Ferrari
- Hematology; Arcispedale Santa Maria Nuova-IRCCS; Reggio Emilia Italy
| | - A. Molinari
- Hematology; Ospedale degli Infermi; Rimini (FC) Italy
| | - A.M. Liberati
- Department of Oncohematology; S.Maria Hospital; Terni Italy
| | - A. Conconi
- Unit of Hematology; Department of Internal Medicine, Ospedale degli Infermi; Ponderano (BI) Italy
| | - P. Matteucci
- Haematology and Bone Marrow Transplantation Unit; Fondazione IRCCS Istituto Nazionale dei Tumori; Milan Italy
| | - S. Pozzi
- Department of Diagnostic, Clinical and Public Health Medicine; University of Modena and Reggio Emilia; Modena Italy
| | - M. Musso
- Division of Hematology; La Maddalena Hospital; Palermo Italy
| | - C. Mammi
- GRADE onlus; Gruppo Amici dell'Ematologia; Reggio Emilia Italy
| | - F. Monaco
- Hematology Unit; Antonio e Biagio e Cesare Arrigo Hospital; Alessandria Italy
| | - S. Ferrero
- Division of Hematology; University of Torino; Torino Italy
| | - A. Tucci
- Hematology; Spedali Civili Hospital; Brescia Italy
| |
Collapse
|
43
|
Ghione P, Cavallo F, Visco C, Chen Z, Nicolosi M, Castellino A, Tisi M, Dogliotti I, Boccadoro M, Leonard J, Vitolo U, Martin P. Retrospective analysis on R-DHAP/OX and ASCT as salvage treatment for relapsed/refractory high-risk follicular lymphoma. Hematol Oncol 2017. [DOI: 10.1002/hon.2439_119] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- P. Ghione
- Department of Molecular Biotechnologies and Health Sciences; Universita' di Torino; Torino Italy
| | - F. Cavallo
- Department of Molecular Biotechnologies and Health Sciences; Universita' di Torino; Torino Italy
| | - C. Visco
- Cell Therapy and Hematology; San Bortolo Hospital; Vicenza Italy
| | - Z. Chen
- Division of Biostatistics and Epidemiology; Weill Cornell Medicine; New York New York USA
| | - M. Nicolosi
- Hematology 2, Citta' della Salute e della Scienza di Torino; Torino Italy
| | - A. Castellino
- Hematology 2, Citta' della Salute e della Scienza di Torino; Torino Italy
| | - M.C. Tisi
- Cell Therapy and Hematology; San Bortolo Hospital; Vicenza Italy
| | - I. Dogliotti
- Department of Molecular Biotechnologies and Health Sciences; Universita' di Torino; Torino Italy
| | - M. Boccadoro
- Department of Molecular Biotechnologies and Health Sciences; Universita' di Torino; Torino Italy
| | - J.P. Leonard
- Hematology and Medical Oncology, Weill Cornell Medicine; New York New York USA
| | - U. Vitolo
- Hematology 2, Citta' della Salute e della Scienza di Torino; Torino Italy
| | - P. Martin
- Hematology and Medical Oncology, Weill Cornell Medicine; New York New York USA
| |
Collapse
|
44
|
Lasagni A, Giordano P, Lacilla M, Raviolo A, Trento M, Camussi E, Grassi G, Charrier L, Cavallo F, Albera R, Porta M, Zanone MM. Cochlear, auditory brainstem responses in Type 1 diabetes: relationship with metabolic variables and diabetic complications. Diabet Med 2016; 33:1260-7. [PMID: 26605750 DOI: 10.1111/dme.13039] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 11/18/2015] [Indexed: 01/29/2023]
Abstract
AIMS Few studies have analysed the presence of hearing abnormalities in diabetes. We assessed the presence of subclinical auditory alterations and their possible association with early vascular and neurological dysfunction in young adults with Type 1 diabetes of long duration. METHODS Thirty-one patients with Type 1 diabetes (mean age 33 ± 2.3 years, disease duration 25.7 ± 4.2 years) and 10 healthy controls underwent pure tone audiometry (PTA), distortion product otoacoustic emission (DPOAE) and auditory brainstem response (ABR) analyses. Associations with metabolic variables and chronic complications were explored. RESULTS Compared with healthy controls, patients with diabetes had significantly higher mean hearing thresholds, although still within the normoacusic range. DPOAE intensities at medium frequencies (2.8-4 kHz) were significantly lower in patients with diabetes. In ABR, in addition to waves I, III and V, we observed the appearance of a visible wave IV in patients with diabetes compared with controls (prevalence 61% vs. 10%, P < 0.05), and its appearance was related to a prolonged I-V interval (4.40 ± 0.62 ms vs. 4.19 ± 0.58 ms, P < 0.05). Diastolic blood pressure was higher in people with abnormal DPOAE (P < 0.05), whereas systolic blood pressure correlated with wave V and interpeak I-V interval latencies. A trend towards an association between evidence of wave IV and the presence of somatic neuropathy or abnormal cardiovascular autonomic tests was observed. CONCLUSIONS Young adults with long-term Type 1 diabetes have subclinical abnormalities in qualitative auditory perception, despite normal hearing thresholds, which might reflect neuropathic and/or vascular alterations.
Collapse
Affiliation(s)
- A Lasagni
- Department of Medical Sciences, University of Turin, Turin, Italy
| | - P Giordano
- Department of Surgical Sciences, University of Turin, Turin, Italy
| | - M Lacilla
- Department of Surgical Sciences, University of Turin, Turin, Italy
| | - A Raviolo
- Department of Medical Sciences, University of Turin, Turin, Italy
| | - M Trento
- Department of Medical Sciences, University of Turin, Turin, Italy
| | - E Camussi
- Department of Public Health and Pediatric Sciences, University of Turin, Turin, Italy
| | - G Grassi
- Department of Medical Sciences, University of Turin, Turin, Italy
| | - L Charrier
- Department of Public Health and Pediatric Sciences, University of Turin, Turin, Italy
| | - F Cavallo
- Department of Public Health and Pediatric Sciences, University of Turin, Turin, Italy
| | - R Albera
- Department of Surgical Sciences, University of Turin, Turin, Italy
| | - M Porta
- Department of Medical Sciences, University of Turin, Turin, Italy
| | - M M Zanone
- Department of Medical Sciences, University of Turin, Turin, Italy
| |
Collapse
|
45
|
De Robertis M, Arigoni M, Loiacono L, Riccardo F, Calogero R, Feodorova Y, Tashkova D, Belovejdov V, Sarafian V, Cavallo F, Signori E. Novel insights into Notum and glypicans regulation in colorectal cancer. Eur J Cancer 2016. [DOI: 10.1016/s0959-8049(16)61546-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
46
|
Lo Iacono M, Cavallo F, Quaglino E, Rolla S, Iezzi M, Pupa SM, De Giovanni C, Lollini PL, Musiani P, Forni G, Calogero RA. A Limited Autoimmunity to p185neu Elicited by DNA and Allogeneic Cell Vaccine Hampers the Progression of Preneoplastic Lesions in HER-2/NEU Transgenic Mice. Int J Immunopathol Pharmacol 2016; 18:351-63. [PMID: 15888257 DOI: 10.1177/039463200501800217] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023] Open
Abstract
Prevention of the progression of precancerous lesions by vaccines is a virtually uncharted territory. Their potential, however, is being assessed in transgenic mice which develop autochthonous tumors with defined stages of progression. In this paper we show that the DNA micro-array technology significantly helps assessment of the preventive efficacy of a combined DNA and cell vaccine. All female rat Her-2/neu transgenic BALB/c (BALB-neuT) mice develop an invasive carcinoma in each of their mammary glands within 25 weeks of age. This is elicited by the activated transforming rat Her-2/neu oncogene embedded in their genome. We have previously shown that vaccination of mice bearing multiple in situ carcinomas with DNA plasmids which code for the extracellular and transmembrane domain of rat p185neu, the product of the rat Her-2/neu oncogene, followed by a boost with rat p185neu+ allogeneic cells engineered to secrete interferon-γ, keeps 48% of mice tumor free until week 32. We have now extended our follow-up until mice reach one year of age and show that protection vanishes as time progresses. This observation suggests that the accuracy of the results studying immunotherapy against life-threatening tumors is a function of the length of the follow-up. The application of microarrays, and the concordance of morphologic and gene expression data led us to identify antibody as the main mechanism induced by vaccination. Protection is associated with a break of tolerance and a limited autoimmunity against the
Collapse
Affiliation(s)
- M Lo Iacono
- Department of Clinical and Biological Sciences, University of Turin, Orbassano, Italy
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Piras LA, Riccardo F, Iussich S, Maniscalco L, Gattino F, Martano M, Morello E, Lorda Mayayo S, Rolih V, Garavaglia F, De Maria R, Lardone E, Collivignarelli F, Mignacca D, Giacobino D, Ferrone S, Cavallo F, Buracco P. Prolongation of survival of dogs with oral malignant melanoma treated by en bloc surgical resection and adjuvant CSPG4-antigen electrovaccination. Vet Comp Oncol 2016; 15:996-1013. [PMID: 27146852 DOI: 10.1111/vco.12239] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2016] [Revised: 03/14/2016] [Accepted: 03/29/2016] [Indexed: 12/19/2022]
Abstract
Reported post-surgery 1-year survival rate for oral canine malignant melanoma (cMM) is around 30%; novel treatments are needed as the role of adjuvant chemotherapy is unclear. This prospective study regards adjuvant electrovaccination with human chondroitin sulfate proteoglycan-4 (hCSPG4)-encoded plasmid in 23 dogs with resected II/III-staged CSPG4-positive oral cMM compared with 19 dogs with resected only II/III-staged CSPG4-positive oral cMM. Vaccination resulted in 6-, 12-, 18- and 24-month survival rate of 95.6, 73.9, 47.8 and 30.4%, respectively [median survival time (MST) 684 days, range 78-1694, 8 of 23 dogs alive] and 6-, 12-, 18- and 24-month disease-free interval (DFI) rate of 82.6, 47.8, 26.1 and 17.4%, respectively (DFI 477 days, range 50-1694). Non-vaccinated dogs showed 6-, 12-, 18- and 24-month survival rate of 63.2, 26.3, 15.8 and 5.3%, respectively (MST 200 days, range 75-1507, 1 of 19 dogs alive) and 6-, 12-, 18- and 24-month DFI rate of 52.6, 26.3, 10.5 and 5.3%, respectively (DFI 180 days, range 38-1250). Overall survival and DFI of vaccinated dogs was longer in those <20 kg. In vaccinated and non-vaccinated dogs local recurrence rate was 34.8 and 42%, respectively while lung metastatic rate was 39 and 79%, respectively.
Collapse
Affiliation(s)
- L A Piras
- Department of Veterinary Sciences, University of Torino, Torino, Italy
| | - F Riccardo
- Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, University of Torino, Torino, Italy
| | - S Iussich
- Department of Veterinary Sciences, University of Torino, Torino, Italy
| | - L Maniscalco
- Department of Veterinary Sciences, University of Torino, Torino, Italy
| | - F Gattino
- Department of Veterinary Sciences, University of Torino, Torino, Italy
| | - M Martano
- Department of Veterinary Sciences, University of Torino, Torino, Italy
| | - E Morello
- Department of Veterinary Sciences, University of Torino, Torino, Italy
| | - S Lorda Mayayo
- Department of Veterinary Sciences, University of Torino, Torino, Italy
| | - V Rolih
- Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, University of Torino, Torino, Italy
| | - F Garavaglia
- Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, University of Torino, Torino, Italy
| | - R De Maria
- Department of Veterinary Sciences, University of Torino, Torino, Italy
| | - E Lardone
- Department of Veterinary Sciences, University of Torino, Torino, Italy
| | | | - D Mignacca
- Clinica Veterinaria Roma Sud, Roma, Italy
| | - D Giacobino
- Department of Veterinary Sciences, University of Torino, Torino, Italy
| | - S Ferrone
- Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
| | - F Cavallo
- Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, University of Torino, Torino, Italy
| | - P Buracco
- Department of Veterinary Sciences, University of Torino, Torino, Italy
| |
Collapse
|
48
|
Conzo G, Docimo G, Mauriello C, Gambardella C, Esposito D, Cavallo F, Tartaglia E, Napolitano S, Santini L. The current status of lymph node dissection in the treatment of papillary thyroid cancer. A literature review. Clin Ter 2016; 164:e343-6. [PMID: 24045534 DOI: 10.7417/ct.2013.1599] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
AIM Cervical lymph node micrometastases are observed in up to 90% of papillary thyroid cancers (PTC), showing that lymph nodal involvement is very common. Nevertheless, during the last years, the role of lymph node dissection in the treatment of PTC has been controversial and, at present, the best indications to the routine or therapeutic neck dissection remain subject of research. In order to better analyze the current role of lymph node dissection in the surgical treatment of PTC, an analysis of the most recent literature data was performed. STUDY DESIGN By using as keywords lymph node dissection, selective, lateral or central lymph node dissection, modified radical neck dissection, prophylactic or therapeutic lymph node dissection, papillary thyroid cancer, a Pub Med data base research was carried out. The most recent guidelines of different referral endocrine societies, inhering neck dissection for PTC, were also evaluated. RESULTS The role of neck dissection in PTC management remains controversial regarding routine or therapeutic indications, surgical extension, and its impact on local recurrence and long term survival. Due to inhomogeneous literature data, the current status of node dissection is still subject of research. CONCLUSIONS There is agreement between endocrine and neck surgeons about the extension of therapeutic lymph node dissection in N+ PTC patients , and also in the prophylactic treatment of N0 "high risk" patients. Considering a recent trend toward routine central lymphadenectomy avoiding radioactive treatment, prospective randomized trials are needed to evaluate the benefits of different approaches.
Collapse
Affiliation(s)
- G Conzo
- Department of Anaesthesiologic, Surgical and Emergency Sciences. Second University of Naples. Italy
| | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Conzo G, Tartaglia E, Gambardella C, Esposito D, Sciascia V, Mauriello C, Nunziata A, Siciliano G, Izzo G, Cavallo F, Thomas G, Musella M, Santini L. Minimally invasive approach for adrenal lesions: Systematic review of laparoscopic versus retroperitoneoscopic adrenalectomy and assessment of risk factors for complications. Int J Surg 2015; 28 Suppl 1:S118-23. [PMID: 26708860 DOI: 10.1016/j.ijsu.2015.12.042] [Citation(s) in RCA: 76] [Impact Index Per Article: 8.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2015] [Revised: 04/18/2015] [Accepted: 05/10/2015] [Indexed: 02/06/2023]
Abstract
In the last decades, minimally invasive transperitoneal laparoscopic adrenalectomy has become the standard of care for surgical resection of the adrenal gland tumors. Recently, however, adrenalectomy by a mininvasive retroperitoneal approach has reached increasingly popularity as alternative technique. Short hospitalization, lower postoperative pain and decrease of complications and a better cosmetic resolution are the main advantages of these innovative techniques. In order to determine the better surgical management of adrenal neoplasms, the Authors analyzed and compared the feasibility and the postoperative complications of minimally invasive adrenalectomy approaches. A systematic research of the English literature, including major meta-analysis articles, clinical randomized trials, retrospective studies and systematic reviews was performed, comparing laparoscopic transperitoneal adrenalectomy versus retroperitoneoscopic adrenalectomy. Many studies support that posterior retroperitoneal adrenalectomy is superior or at least comparable to laparoscopic transperitoneal adrenalectomy in operation time, pain score, blood loss, hospitalization, complications rates and return to normal activity. However, laparoscopic transperitoneal adrenalectomy is up to now a safe and standardized procedure with a shorter learning curve and a similar low morbidity rate, even for tumors larger than 6 cm. Nevertheless, further studies are needed to objectively evaluate these techniques, excluding selection bias and bias related to differences in surgeons' experiences with this approaches.
Collapse
Affiliation(s)
- G Conzo
- Unit of General and Oncologic Surgery, Department of Anesthesiologic, Surgical and Emergency Sciences, School of Medicine and Surgery Second University of Naples, Italy.
| | - E Tartaglia
- Unit of General and Oncologic Surgery, Department of Anesthesiologic, Surgical and Emergency Sciences, School of Medicine and Surgery Second University of Naples, Italy.
| | - C Gambardella
- Unit of General and Oncologic Surgery, Department of Anesthesiologic, Surgical and Emergency Sciences, School of Medicine and Surgery Second University of Naples, Italy.
| | - D Esposito
- Unit of General and Oncologic Surgery, Department of Anesthesiologic, Surgical and Emergency Sciences, School of Medicine and Surgery Second University of Naples, Italy.
| | - V Sciascia
- Unit of General and Oncologic Surgery, Department of Anesthesiologic, Surgical and Emergency Sciences, School of Medicine and Surgery Second University of Naples, Italy.
| | - C Mauriello
- Unit of General and Oncologic Surgery, Department of Anesthesiologic, Surgical and Emergency Sciences, School of Medicine and Surgery Second University of Naples, Italy.
| | - A Nunziata
- Unit of General and Oncologic Surgery, Department of Anesthesiologic, Surgical and Emergency Sciences, School of Medicine and Surgery Second University of Naples, Italy.
| | - G Siciliano
- Unit of General and Oncologic Surgery, Department of Anesthesiologic, Surgical and Emergency Sciences, School of Medicine and Surgery Second University of Naples, Italy.
| | - G Izzo
- Unit of General and Oncologic Surgery, Department of Anesthesiologic, Surgical and Emergency Sciences, School of Medicine and Surgery Second University of Naples, Italy.
| | - F Cavallo
- Unit of General and Oncologic Surgery, Department of Anesthesiologic, Surgical and Emergency Sciences, School of Medicine and Surgery Second University of Naples, Italy.
| | - G Thomas
- Unit of General and Oncologic Surgery, Department of Anesthesiologic, Surgical and Emergency Sciences, School of Medicine and Surgery Second University of Naples, Italy.
| | - M Musella
- Advanced Biomedical Sciences Department, AOU "Federico II", Naples, Italy.
| | - L Santini
- Unit of General and Oncologic Surgery, Department of Anesthesiologic, Surgical and Emergency Sciences, School of Medicine and Surgery Second University of Naples, Italy.
| |
Collapse
|
50
|
Merli F, Tucci A, Angrilli F, Cavallo F, Cabras G, Fabbri A, Mammi C, Chiappella A, Gussetti D, Zilioli V, Arcari A, Tani M, Balzarotti M, Fedina A, Marcheselli L, Spina M. The “Elderly Project” by the Fondazione Italiana Linfomi (FIL): a prospective multidimensional assessment of elderly patients with diffuse large B-cell lymphoma. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv348.08] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|